thiazoles has been researched along with imatinib mesylate in 571 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 232 (40.63) | 29.6817 |
| 2010's | 334 (58.49) | 24.3611 |
| 2020's | 5 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Corey, SJ; Dai, Y; Dent, P; Grant, S; Rahmani, M | 1 |
| Travis, J | 1 |
| Chen, P; Lee, FY; Norris, D; Sawyers, CL; Shah, NP; Tran, C | 1 |
| Nelson, L | 1 |
| Jones, SB; Lu, HY; Lu, Q | 1 |
| Doggrell, SA | 1 |
| Sarabu, R | 1 |
| Cowan-Jacob, SW; Deininger, MW; Druker, BJ; Heinrich, MC; Jia, T; Lee, FY; Manley, PW; Mestan, J; O'Hare, T; Stoffregen, EP; Walters, DK | 1 |
| Deininger, MW; Druker, BJ; Heinrich, MC; O'Hare, T; Sherbenou, DW; Stoffregen, EP; Walters, DK | 1 |
| D'Antonio, J | 1 |
| Brabant, G; Jakubcakova, V; Kant, S; Kremenevskaja, N; Rao, AS; Resch, J; von Wasielewski, R | 1 |
| Shah, NP | 1 |
| Corbin, AS; Druker, BJ; O'Hare, T | 1 |
| Bokemeyer, C; Corbin, AS; Deininger, MW; Druker, BJ; Griffith, D; Heinrich, MC; Lee, FY; Schittenhelm, MM; Schroeder, A; Shiraga, S | 1 |
| Biggs, WH; Chao, LH; Kuriyan, J; Lockhart, DJ; Milanov, ZV; Patel, HK; Sawyers, CL; Seeliger, M; Shah, NP; Treiber, DK; Young, MA; Zarrinkar, PP | 1 |
| Akin, C; Donker, M; Jiang, Y; Lee, FY; Luo, R; Shah, NP | 1 |
| Hampton, T | 1 |
| Bhalla, KN; Chen, Z; Lee, FY; Wu, J | 1 |
| Allan, EK; Baird, JW; Barow, M; Copland, M; Elrick, LJ; Hamilton, A; Holyoake, TL; Jordanides, N; Mountford, JC | 1 |
| Meier, KE; Zhang, Z | 1 |
| Calabretta, B; Cattelani, S; Donato, NJ; Ferrari-Amorotti, G; Guerzoni, C; Iotti, G; Keeshan, K; Zattoni, M | 1 |
| Ohnishi, K | 2 |
| Cortes, J; Quintás-Cardama, A | 4 |
| Borzillerri, R; Chang, CY; Cheng, JD; Kiefer, SE; Kish, K; Klei, HE; Lee, FY; Lombardo, LJ; Newitt, JA; Tokarski, JS; Wittekind, M; Xie, D; Zhang, Y | 1 |
| Bradeen, HA; Deininger, MW; Druker, BJ; Eide, CA; Johnson, KJ; Lee, FY; O'Hare, T; Willis, SG | 1 |
| Blackwood-Chirchir, MA; Bleickardt, E; Chen, TT; Cortes, J; Decillis, AP; Donato, N; Huang, F; Iyer, V; Kantarjian, H; Nicaise, C; Nicoll, J; O'Brien, S; Paquette, R; Sawyers, CL; Shah, NP; Talpaz, M | 1 |
| Druker, BJ | 1 |
| Assouline, S; Gambacorti-Passerini, C; Laneuville, P | 1 |
| Fricker, J | 1 |
| Chomel, JC; Guilhot, F; Martineau, G; Roy, L; Sorel, N; Turhan, AG | 1 |
| Chu, SC; Li, CC; Tang, JL | 1 |
| Curtiss, FR | 1 |
| Cortes, J; Giles, F; Jones, D; Kantarjian, H; Nicaise, C; O'Brien, S; Quintas-Cardama, A; Talpaz, M | 1 |
| Balasis, M; Bali, P; Bhalla, K; Estrella, V; Fiskus, W; Herger, B; Kumaraswamy, S; Lee, F; Pranpat, M; Rao, R; Richon, V; Rocha, K | 1 |
| Duffy, TM; Hu, Y; Lee, FY; Li, S; Swerdlow, S; Weinmann, R | 1 |
| Ahmed, S; Andreoni, F; Boschelli, F; Cleris, L; Coluccia, AM; Donella-Deana, A; Formelli, F; Gambacorti-Passerini, C; Magistroni, V; Marchesi, E; Piazza, R; Puttini, M; Redaelli, S; Scapozza, L | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Countouriotis, AM; Druker, BJ; Ezzeddine, R; Facon, T; Goldberg, SL; Hochhaus, A; Hughes, TP; Kantarjian, HM; Lipton, JH; Muller, MC; Niederwieser, D; Shah, NP; Silver, RT; Stone, RM | 1 |
| Cortes, J; Kantarjian, H; Quintás-Cardama, A | 2 |
| Agarwal, P; Apperley, J; Baccarani, M; Branford, S; Cortes, J; Coutre, S; Erben, P; Gollerkeri, A; Guilhot, F; Hamerschlak, N; Hochhaus, A; Kim, DW; Ottmann, O; Ritchie, E; Rousselot, P; Saglio, G; Shah, N | 1 |
| Chabane, K; Hayette, S; Magaud, JP; Michallet, M; Nicolini, FE; Tigaud, I | 1 |
| Akahane, D; Nunoda, K; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Sashida, G; Takaku, T; Tauchi, T | 1 |
| Dent, P; Grant, S; Harada, H; Nguyen, TK; Rahmani, M | 1 |
| Chen, XG; Liu, H | 1 |
| Czyz, M; Jakubowska, J | 1 |
| Agarwal, P; Amadori, S; Apperley, J; Baccarani, M; Branford, S; Bullorsky, EO; de Souza, CA; Gollerkeri, A; Guilhot, F; Heim, D; Hochhaus, A; Kim, DW; Larson, RA; Lipton, JH; Muller, MC; Roboz, GJ; Talpaz, M | 1 |
| Tuma, RS | 2 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S | 1 |
| Maekawa, T | 1 |
| Kimura, S | 5 |
| Countouriotis, A; Golenkov, A; Hamerschlak, N; Hellmann, A; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Khoroshko, N; Masszi, T; Pasquini, R; Radich, J; Robak, T; Rousselot, P; Shah, N; Skotnicki, A; Zaritsky, A | 1 |
| Baccarani, M; Castagnetti, F; Colarossi, S; Gnani, A; Martinelli, G; Paolini, S; Rondoni, M; Rosti, G; Soverini, S | 1 |
| Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 1 |
| Heaney, NB; Holyoake, TL | 1 |
| Aguilon, P; Charbonnier, A; Gisserot, O; Mozziconacci, MJ; Olschwang, S; Popovici, C; Rémy, V | 1 |
| von Mehren, M | 1 |
| Cannell, E | 1 |
| Ault, P | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 3 |
| Apanovitch, AM; Coutre, S; Dombret, H; Gollerkeri, A; Guilhot, F; Hochhaus, A; Larson, RA; Martinelli, G; Ottmann, O; Radich, J; Rege-Cambrin, G; Simonsson, B | 1 |
| Erben, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Seifarth, W | 1 |
| Corm, S; Grardel, N; Preudhomme, C; Quesnel, B; Rad-Quesnel, E; Renneville, A | 1 |
| Schiffer, CA | 1 |
| Oestreicher, P | 2 |
| Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC | 1 |
| Martinelli, G; Paolini, S; Piccaluga, PP | 1 |
| Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ | 1 |
| Blaser, BW; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Druker, BJ; Eiring, AM; Gambacorti-Passerini, C; Liu, S; Marcucci, G; Muthusamy, N; Neviani, P; Notari, M; Oaks, JJ; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Verrills, NM | 1 |
| Bennett, KL; Colinge, J; Dürnberger, G; Fernbach, NV; Hantschel, O; Kaupe, I; Köcher, T; Planyavsky, M; Remsing Rix, LL; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Borthakur, G; Bruzzi, J; Cortes, J; Kantarjian, H; Munden, R; O'brien, S; Quintás-Cardama, A | 1 |
| Bacher, U; Haferlach, C; Haferlach, T; Hertenstein, B; Kern, W; Schnittger, S | 1 |
| Brodzik, F; Mehdi, S; Pasquale, D; Ramanarayanan, J | 1 |
| Antolino, A; Berretta, S; Di Raimondo, F; Giustolisi, R; Massimino, M; Messina, A; Stagno, F; Stella, S; Vigneri, P | 1 |
| Alimena, G; Breccia, M; Cannella, L; Nanni, M; Stefanizzi, C | 1 |
| Chiusolo, P; Farina, G; Fiorini, A; Leone, G; Reddiconto, G; Sica, S; Sorà, F | 1 |
| Holyoake, TL; Jørgensen, HG | 1 |
| Thomas, X | 1 |
| Frame, D | 3 |
| Anand, M; Apperley, JF; Babb, A; de Lavallade, H; De Melo, V; Ghorashian, S; Goldman, JM; Kaeda, JS; Khorashad, JS; Marin, D; Mehta, P; Milojkovic, D; Olavarria, E; Reid, AG | 1 |
| Faivre, S; Le Tourneau, C; Raymond, E | 1 |
| Brandwein, J | 1 |
| Hochhaus, A | 1 |
| Fausel, C; Frame, D; Sessions, J | 1 |
| Fausel, C | 1 |
| Kujawski, L; Talpaz, M | 1 |
| Dobrovic, A; Kovalenko, S; McBean, M; Ritchie, DS; Seymour, JF; Westerman, DA | 1 |
| Allan, EK; Copland, M; Hamilton, A; Holyoake, TL; Lee, FY; Pellicano, F; Richmond, L; Weinmann, R | 1 |
| Steinberg, M | 1 |
| Hirano, I; Nakamura, S; Ohnishi, K; Okinaka, K; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y | 1 |
| Ashihara, E; Deguchi, Y; Fujiyama, Y; Hodohara, K; Kimura, S; Maekawa, T; Niwa, T | 1 |
| Corm, S; Hetuin, D; Idziorek, T; Joha, S; Liu, J; Philippe, N; Preudhomme, C; Quesnel, B | 1 |
| Booth, B; Brave, M; Bullock, J; Farrell, A; Gobburu, J; Goodman, V; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kenna, L; Men, A; Morse, D; Noory, C; Pazdur, R; Pope, S; Ramchandani, R; Saber, H; Sridhara, R; Timmer, W | 1 |
| Bui, B; Italiano, A | 1 |
| Baldwin, AS; Duncan, EA; Goetz, CA; Mayo, KJ; Sawyers, CL; Skaggs, BJ; Stein, SJ; Ziegelbauer, K | 1 |
| Apperley, J; Chaidos, A; Dannie, E; Davis, J; Gabriel, I; Goldman, J; Marin, D; Sorouri, J | 1 |
| Liu, XL; Zhang, S; Zhu, HQ | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Muscaritoli, M; Stefanizzi, C | 1 |
| Aulitzky, WE; Duyster, J; Fanta, S; Miething, C; Skorta, I; Sonnenberg, M; van der Kuip, H | 1 |
| Cortes, J; Kantarjian, H | 2 |
| Hantschel, O; Rix, U; Superti-Furga, G | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Corm, S; Countouriotis, AM; Deininger, M; Dombret, H; Ezzeddine, R; Goldberg, SL; Hochhaus, A; Hughes, T; Kantarjian, HM; Larson, RA; Lipton, JH; Müller, MC; Niederwieser, D; Roy, L; Shah, NP; Silver, RT; Stone, RM | 1 |
| Cools, J; Cortes, J; Garcia-Manero, G; Gilliland, DG; Kantarjian, H; Lee, F; Lennon, PA; Manshouri, T; Quintás-Cardama, A; Tong, W; Vega, F | 1 |
| Fandi, A; Lee, F; Voi, M | 1 |
| Cowan-Jacob, SW; Fendrich, G; Grzesiek, S; Jahnke, W; Manley, PW; Strauss, A; Vajpai, N | 1 |
| Barańska, M; Gniot, M; Iwoła, M; Komarnicki, M; Lewandowska, M; Lewandowski, K | 1 |
| DiPersio, JF; Ramirez, P | 1 |
| Cobanoglu, U; Omay, SB; Ovali, E; Sonmez, M | 1 |
| Bajel, A; Bassili, S; Seymour, JF | 1 |
| Craig, J; Cunningham, J; Gelly, K; Pippard, MJ; Sales, M; Tauro, S; Walker, K | 1 |
| Barlow, A; Doig, A; Drummond, MW; Robertson, M; Stewart, W | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J; Tam, CS | 1 |
| Valent, P | 2 |
| Bleickardt, E; Charbonnier, A; Collins, RH; Deininger, M; Dorlhiac-Llacer, PE; Francis, S; Hochhaus, A; Hughes, T; Kantarjian, HM; Khoroshko, N; Khoury, HJ; Kim, DW; Milone, JH; Otero, I; Paquette, RL; Réa, D; Shah, NP; Silver, RT; Strauss, L; Vela-Ojeda, J | 1 |
| Appell, KC; Beasley, JR; Carroll, CD; Lin, T; Rokosz, LL; Webb, ML; Zhao, J | 1 |
| Dang, P; Eadie, L; Frede, A; Hewett, D; Hiwase, DK; Hughes, TP; Kumar, S; Melo, J; Saunders, V; To, LB; White, DL; Zrim, S | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Deininger, MW | 1 |
| Amabile, M; Arruga, F; Baccarani, M; Baruzzi, A; Berton, G; Chiaretti, S; Cilloni, D; Foà, R; Giannoulia, P; Iacobucci, I; Lonetti, A; Martinelli, G; Messa, F; Ottaviani, E; Pane, F; Paolini, S; Papayannidis, C; Perini, G; Piccaluga, PP; Poerio, A; Saglio, G; Soverini, S; Vitale, A | 1 |
| Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
| Clark, RE; Davies, A; Giannoudis, A; Harris, RJ; Lucas, CM; Pirmohamed, M | 1 |
| Brümmendorf, TH; Corm, S; Cortes, J; Coutre, S; Ernst, T; Gambacorti-Passerini, C; Hamerschlak, N; Hochhaus, A; Khoury, HJ; Kim, DW; Martinelli, G; Michallet, M; Radich, JP; Raffoux, E; Rege-Cambrin, G; Ritchie, E; Roy, L; Talpaz, M; Tang, JL; Van Tornout, JM; Zhu, C | 1 |
| Distler, JH; Distler, O | 1 |
| Cools, J; De Keersmaecker, K; Hantschel, O; Superti-Furga, G; Versele, M | 1 |
| Burger, J; Cortes, J; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N | 1 |
| Wang, ES; Wetzler, M; Zeidan, A | 1 |
| Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F | 1 |
| Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Usui, N | 1 |
| Kubuki, Y | 1 |
| Hohl, RJ; Holstein, SA; Stokes, JB | 1 |
| Bewry, NN; Boulware, D; Emmons, MF; Hazlehurst, LA; Nair, RR; Pinilla-Ibarz, J | 1 |
| Alnadaf, T; Buchdunger, E; Day, E; Jarai, G; Manley, PW; Spiegel, K; Walker, C; Waters, B | 1 |
| Deliliers, GL; Ghidoni, R; Onida, F; Radaelli, F; Ricci, C; Saporiti, G; Servida, F; Todoerti, K | 1 |
| Balbas, M; Bleickardt, E; Kasap, C; Nicaise, C; Nicoll, JM; Sawyers, CL; Shah, NP; Weier, C | 1 |
| Chuah, C; Melo, JV | 1 |
| Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R | 1 |
| Gora-Tybor, J; Robak, T | 1 |
| Cervantes, F | 1 |
| Bendit, I; de Alencar Fischer Chamone, D; de Mello Conchon, MR; Dias, L; Dorlhiac-Llacer, PE; Ferreira, P; Kumeda, C; Lima, W | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Müller, BA | 1 |
| Cayuela, JM; Dombret, H; Maarek, O; Raffoux, E; Rea, D | 1 |
| Cortes, JE; Jabbour, E; Kantarjian, HM | 1 |
| Kantarjian, H | 1 |
| Hantschel, O; Kuriyan, J; Superti-Furga, G; Winger, JA | 1 |
| Cortés, JE; Kantarjian, H; Quintás-Cardama, A | 1 |
| Bixby, DL; Talpaz, M | 1 |
| Cortes, J; Fava, C; Kantarjian, H; Verma, D | 1 |
| Cortes, J; Kantarjian, H; Kornblau, S; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Vidal-Senmache, G; Wierda, W | 1 |
| Cameron, MD; He, Y; Koenig, M; Li, X; Ruiz, CH; Vojkovsky, T | 1 |
| Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S | 1 |
| Au, K; Clements, PJ; Furst, DE; Khanna, D; Tashkin, DP | 1 |
| Baer, T; Beckers, T; Ciossek, T; Dove, S; Eichhorn, E; Mahboobi, S; Maier, T; Pongratz, H; Sellmer, A; Winkler, M | 1 |
| Cortes, JE; Kantarjian, H; Pavlovsky, C | 1 |
| Ahmed, N; Cang, S; Liu, D; Mathews, T; Primanneni, S; Seiter, K; Tan, J | 1 |
| Tyler, T | 1 |
| Mauro, MJ | 3 |
| Duncan, C; Galviz, G; Hsieh, Y; Zhou, Q | 1 |
| Giles, FJ | 2 |
| Bellodi, C; Calabretta, B; Dinsdale, D; Donato, N; Dyer, MJ; Galavotti, S; Hamilton, A; Helgason, GV; Holyoake, T; Hunter, A; Lidonnici, MR; Nicotera, P; Ronchetti, M; Salomoni, P; Selmi, T; Soliera, AR; Tirrò, E; Van Etten, RA; Vigneri, P; Yacobi, R; Young, KW | 1 |
| Alimena, G; Breccia, M; Cannella, L; Napoleone, L; Santopietro, M; Stefanizzi, C | 1 |
| Bradley-Garelik, MB; Cortes, J; DiPersio, J; Dorlhiac-Llacer, P; Kantarjian, H; Khoroshko, N; Khoury, HJ; Kim, DW; Müller, MC; Pasquini, R; Radich, JP; Tallman, MS; Zhu, C | 1 |
| Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR | 1 |
| Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R | 1 |
| Albitar, M; Bornmann, W; Estrov, Z; Faderl, S; Harris, D; Hazan-Halevy, I; Kantarjian, HM; Liu, Z; Maxwell, D; Pal, A; Peng, Z; Van, Q | 1 |
| Gruber, F; Mustjoki, S; Porkka, K | 1 |
| Jillella, AP; Salama, ME; Ustun, C | 1 |
| Plattner, R; Sims, JT | 1 |
| Bleickardt, E; Borthakur, G; Chen, TT; Cortes, JE; Kantarjian, HM; Liu, D; O'Brien, S; Quintás-Cardama, A; Ravandi, F | 1 |
| Scuffham, PA; Taylor, MJ | 1 |
| Cortes, J; Han, X; Kantarjian, H; Quintás-Cardama, A | 1 |
| Isidori, A; Malagola, M; Piccaluga, P; Visani, G | 1 |
| Baietto, L; D'Avolio, A; De Francia, S; De Martino, F; Di Carlo, F; Di Perri, G; Pirro, E; Racca, S; Saglio, G; Siccardi, M; Simiele, M | 1 |
| Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Colaci, E; Foà, R; Iori, AP; Latagliata, R; Martinelli, G; Palandri, F; Rosti, G; Torelli, GF; Usai, S; Valle, V | 1 |
| Storey, S | 1 |
| Abruzzese, E; Apperley, JF; Bullorsky, EO; Cortes, JE; de Souza, CA; Erben, P; Heim, D; Hochhaus, A; Hughes, TP; Khoury, HJ; Kim, DW; Kim, HJ; Larson, RA; Lipton, JH; Roboz, GJ; Rosti, G; Roy, L; Sillaber, C; Stone, RM; Van Tornout, J | 1 |
| Allart, S; Garcia, C; Gratacap, MP; Martin, V; Payrastre, B; Recher, C; Sié, P; Valéra, MC | 1 |
| Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Bleickardt, E; Cortes, J; Dejardin, D; Hamerschlak, N; Holowiecki, J; Hughes, T; Jootar, S; Kantarjian, H; Lévy, V; Pasquini, R; Shah, NP | 1 |
| Damaj, G; Garidi, R; Marolleau, JP; Parcelier, A; Roszkiewicz, F; Royer, B; Vaida, I | 1 |
| Ottmann, OG; Pfeifer, H | 2 |
| Borthakur, G; Burger, JA; Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; Koller, C; O'Brien, S; Tam, C; Wierda, WG | 1 |
| Cetkovský, P; Klamová, H; Machová Poláková, K; Marková, M; Moravcová, J; Sisková, M | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S | 1 |
| Bovée, JV; Briaire-de Bruijn, IH; de Miranda, NF; Hogendoorn, PC; Schrage, YM; Taminiau, AH; van Oosterwijk, J; van Wezel, T | 1 |
| Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR | 1 |
| Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Müller, MC; Niederwieser, D; Pelz-Ackermann, O; Pfirrmann, M; Porkka, K | 1 |
| Cortes, J; Fava, C | 1 |
| Facoetti, A; Mazzini, G; Nano, R; Ranza, E | 1 |
| Bleickardt, E; Branford, S; Hanfstein, B; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Lambert, A; Lipton, JH; Müller, MC; Radich, J; Rousselot, P | 1 |
| Davies, MA; Fermeglia, M; Gopal, YN; Hwu, P; Ivan, D; Kim, KB; Lazar, AJ; Mills, GB; Papadopoulos, N; Pavan, GM; Podoloff, DA; Pricl, S; Stemke-Hale, K; Trent, JC; Woodman, SE; Yang, D | 1 |
| Abakumov, EM; Chelysheva, EIu; Domracheva, EV; Goriacheva, SR; Gusarova, GA; Khoroshko, ND; Kuznetsov, SV; Misiurin, AV; Sokolova, MA; Stakhina, OV; Turkina, AG; Vinogradova, OIu; Vorontsova, AV | 1 |
| Botta, M; Bruno, O; Radi, M; Schenone, S | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Berger, MG; Chabane, K; Hayette, S; Nicolini, FE; Tchirkov, A; Tournilhac, O | 1 |
| Auclair, C; Bougherara, H; Crépin, R; Poul, MA; Subra, F; Tauc, P | 1 |
| Aloyz, R; Baker, K; Dirnhofer, S; Foulkes, W; Grygorczyk, C; Grygorczyk, R; Hollmann, CA; Martínez-Marignac, VL; Nadeau, J; Tzankov, A | 1 |
| Bruccoleri, RE; Cao, J; Cockett, MI; de Silva, H; He, A; Huang, W; Ji, RR; Jin, Y; Kayne, PS; Neubauer, MG; Neuhaus, IM; Ott, KH; Penhallow, B; Ross-Macdonald, P; Siemers, NO | 1 |
| Goh, HG; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH | 1 |
| Cortés, JE; Jabbour, E; Kantarjian, H | 1 |
| Bauer, S; Romvari, E | 1 |
| Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; La Rosée, P | 1 |
| Bang, S; Chung, HW; Lim, JB; Park, SW; Song, SY; Wen, J | 1 |
| Chan, YY; Kwan, TK; Lie, AK; Liu, HS; Ma, ES; Sim, JP; Wan, TS; Yeung, YM; Yip, SF | 1 |
| Goldstein, JL | 1 |
| Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC | 1 |
| Apperley, JF; Bua, M; de Lavallade, H; Drummond, MW; Foroni, L; Goldman, JM; Holyoake, TL; Khorashad, JS; Marin, D; Milojkovic, D; Nicholson, E; Paliompeis, C; Reid, A; Rezvani, K; Shepherd, P; Szydlo, R | 1 |
| Ashby, CR; Chen, A; Chen, X; Chen, ZS; Hopper-Borge, E; Kuang, YH; Lei, Y; Ouyang, J; Shen, T; Tiwari, AK; Zhou, Y | 1 |
| Tojo, A | 1 |
| Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP | 1 |
| Branford, S; Hughes, TP; Melo, JV | 1 |
| Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Pane, F; Radich, J; Saglio, G; Silver, RT; Simonsson, B | 1 |
| Czyz, A; Komarnicki, M; Kroll, R; Lewandowski, K | 1 |
| Matsunaga, T | 1 |
| Igishi, T; Kodani, M; Matsumoto, S; Matsunami, K; Morita, M; Nakazaki, H; Shigeoka, Y; Shimizu, E; Sumikawa, T; Suyama, H; Takeda, K; Ueda, Y | 1 |
| Chang, MS; Haferlach, C; Haferlach, T; Hofmann, WK; Kang, S; Kato, M; Kawamata, N; Kim, HS; Koeffler, HP; Kohlmann, A; Meixel, A; Mossner, M; Müschen, M; Nowak, D; Nowak, V; Ogawa, S; Paquette, R; Thoenissen, NH; Thoennissen, NH; Weiss, T | 1 |
| Stock, W | 1 |
| Ravandi, F; Santos, FP | 1 |
| Azam, M; Clackson, T; Daley, GQ; Dalgarno, D; Einhorn, W; Huang, WS; Powers, JT; Sawyer, TK; Shakespeare, WC; Zhu, X | 1 |
| Attar, EC; DeAngelo, DJ | 1 |
| Bornmann, WG; Daniels, L; Donato, NJ; Meng, F; Peng, Z; Peterson, LF; Quintás-Cardama, A; Roulston, D; Talpaz, M; Wu, J; Ying, Y | 1 |
| Cortes, J; Hochhaus, A; Kantarjian, HM; La Rosée, P | 1 |
| Brigid Bradley-Garelik, M; Bullorsky, E; Charbonnier, A; Dombret, H; Ehninger, G; Larson, RA; Lilly, MB; Martinelli, G; Müller, MC; Ottmann, OG; Reiffers, JJ; Shah, NP; Zhu, C | 1 |
| Fullmer, A; Jabbour, E | 1 |
| Frankel, AE; Hogge, DE; Kim, HP | 1 |
| Enrico, A; Hochhaus, A; Kantarjian, H; Khoury, HJ; Kim, DW; Lambert, A; Llacer, PE; Matloub, Y; Müller, MC; Rousselot, P; Shah, NP; Silver, RT; Vela-Ojeda, J | 1 |
| Ashihara, E; Fujiyama, Y; Imoto, M; Kawatani, M; Kimura, S; Kuroda, J; Maekawa, T; Nagao, R; Nakahata, T; Osada, H; Takeuchi, M; Tanaka, R; Tsuruo, T; Umezawa, K; Yasui, E; Yokota, A | 1 |
| Grünebach, F; Hilpert, J; Krusch, M; Placke, T; Salih, HR; Salih, J; Steinle, A | 1 |
| Bijlmakers, MJ; Dibb, NJ; Giannini, AL; Lee, KC; Ouwehand, I; Thomas, NS | 1 |
| Ashman, LK; Griffith, R; Mashkani, B | 1 |
| Akiyama, H; Fukuda, S; Kobayashi, T; Nagata, Y; Ohashi, K; Sakamaki, H; Yamashita, T | 1 |
| Adenis, A; Blay, JY; Bonvalot, S; Bouché, O; Bui, BN; Cioffi, A; Domont, J; Hermine, O; Kinet, JP; Lassau, N; Le Cesne, A; Moussy, A; Ray-Coquard, I | 1 |
| Condorelli, F; Genazzani, AA | 1 |
| Adamia, S; Azam, M; Barrett, R; Cameron, M; Choi, HG; Debiec-Rychter, M; Fletcher, JA; Gray, N; Griffin, JD; Janne, PA; Khosravi-Far, R; Kung, AL; Manley, PW; Mayeda, M; Melo, JV; Moreno, D; Ray, A; Seeliger, M; Sim, T; Weisberg, E; Wu, C; Zhang, J; Zhou, W | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Martinelli, G; Palandri, F; Rosti, G | 1 |
| Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P | 1 |
| Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M | 1 |
| Ahluwalia, MS; Battiwalla, M; Cohen, IL; Francis, J; McCarthy, PL; Paplham, P; Smiley, S; Spangenthal, E; Wang, E; Wetzler, M | 1 |
| Chondropoulos, S; Dervenoulas, J; Economopoulos, T; Economopoulou, C; Ionnidou, ED; Konsioti, F; Papageorgiou, E; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vasilatou, D | 1 |
| Ekblom, M; Juvonen, V; Kairisto, V; Kreutzman, A; Mustjoki, S; Porkka, K; Seggewiss, R; Stenke, L | 1 |
| Beyer, C; Distler, JH; Distler, O | 1 |
| Ambudkar, SV; Bates, SE; Brendel, C; Deeken, JF; Dohse, M; Neubauer, A; Robey, RW; Scharenberg, C; Shukla, S; Volkmann, T | 1 |
| Schiffer, CA; Zonder, JA | 1 |
| Alvarado, Y; Cortes, J; Giles, FJ; Swords, R | 1 |
| Brezinova, J; Cetkovsky, P; Cmunt, E; Dvorakova, D; Faber, E; Indrak, K; Jarosova, M; Klamova, H; Machova-Polakova, K; Markova, M; Mayer, J; Michalova, K; Moravcova, J; Novakova, L; Oltova, A; Voglova, J; Zackova, D | 1 |
| Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
| Borthakur, G; Cortes, J; Estrov, Z; Garcia-Manero, G; Kantarjian, H; Koller, C; O'Brien, S; Shan, J; Verma, D | 1 |
| Albano, F; Anelli, L; Casieri, P; Coccaro, N; Liso, V; Rocchi, M; Rossi, AR; Specchia, G; Vicari, L; Zagaria, A | 1 |
| Adamia, S; Barrett, R; Choi, HG; Deng, X; Gray, N; Griffin, JD; Kung, AL; Moreno, D; Ray, A; Weisberg, E | 1 |
| Baccarani, M; Saglio, G | 1 |
| Abruzzese, E; Baccarani, M; Bhatia, R; Bosly, A; Cortes, J; Dünzinger, U; Facon, T; Fischer, T; Gallagher, NJ; Giles, FJ; Goldberg, S; Jagasia, M; Kam, GL; Kantarjian, HM; Kim, DW; Larson, RA; Mahon, FX; Marin, D; Mendrek, W; Mueller, MC; Rosti, G; Shou, Y | 1 |
| Sawyers, CL | 1 |
| Ayala, M; Baccarani, M; Bleickardt, E; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Huguet, F; Kantarjian, H; Mayer, J; Moiraghi, B; Nakamae, H; Pasquini, R; Shah, NP; Shah, S; Shapiro, D; Shen, Z; Szatrowski, T; Zhu, C | 1 |
| Deininger, MW; Traer, E | 1 |
| Cortés, JE; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| Bradley-Garelik, MB; Cortes, J; Dombret, H; Erben, P; Goh, YT; Hochhaus, A; Maloisel, F; Masszi, T; Paquette, R; Pasquini, R; Saglio, G; Zhu, C | 1 |
| Graves, LM; Lawrence, DS; Martin, TD; Toutchkine, A; Wang, Q; Zimmerman, EI | 1 |
| Alvarez-Calderon, F; Degregori, J; Druker, BJ; Eide, CA; Gregory, MA; Neviani, P; O'Hare, T; Perrotti, D; Phang, TL; Williams, RT; Zaberezhnyy, V | 1 |
| Fielding, AK | 1 |
| Mustjoki, S; Porkka, K; Rohon, P | 1 |
| Chabane, K; Cony-Makhoul, P; Hayette, S; Magaud, JP; Maguer-Satta, V; Michallat, E; Michallet, M; Nicolini, FE; Salesse, S | 1 |
| Joseph, A; Kingham, BF; Martin, SE; Sausen, M | 1 |
| Smith, BD; Stein, B | 1 |
| Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
| Coindre, JM; Debiec-Rychter, M; Dewaele, B; Finalet-Ferreiro, J; Fletcher, CD; Floris, G; Guillou, L; Hogendoorn, PC; Marynen, P; Schöffski, P; Sciot, R; Vandenberghe, P; Vanspauwen, V; Wozniak, A | 1 |
| Alimena, G; Breccia, M | 5 |
| Chen, Y | 1 |
| Antonescu, CR; Besmer, P; Clarkson, B; de Stanchina, E; Giancotti, FG; Manova, K; Rossi, F; Veach, D; Yozgat, Y | 1 |
| Kron, SJ; Sylvester, JE; Veach, DR; Wu, D; Zhou, G | 1 |
| Buclin, T; Decosterd, LA; Duchosal, MA; Haouala, A; Montemurro, M; Widmer, N | 1 |
| Birge, RB; Matsuda, M; Tunceroglu, A | 1 |
| Apperley, JF; Bua, M; Dazzi, F; de Lavallade, H; Foroni, L; Goldman, JM; Ibrahim, AR; Khorashad, JS; Marin, D; Milojkovic, D; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Apperley, JF; Clark, RE; Daghistani, M; De Melo, VA; Foroni, L; Gerrard, G; Goldman, JM; Khorashad, JS; Marin, D; May, PC; Milojkovic, D; Paliompeis, C; Reid, AG; Wang, L | 1 |
| Deininger, M; Hochhaus, A; Jabbour, E | 1 |
| Breccia, M | 1 |
| Cortes, J; Mauro, MJ; Pinilla-Ibarz, J | 1 |
| Arnold, R; Braun, D; Dörken, B; Grille, P; Kim, TD; le Coutre, P; Nogai, H; Plöckinger, U; Schwarz, M; Schweizer, U; Westermann, J | 1 |
| Hassan, AQ; Sharma, SV; Warmuth, M | 1 |
| Alimena, G; Breccia, M; Capria, S; Foà, R; Iori, AP; Meloni, G | 1 |
| Gong, Y; Liu, T; Meng, W; Xing, H | 1 |
| Bencivenga, D; Borriello, A; Caldarelli, I; Cucciolla, V; Danise, P; Della Ragione, F; Oliva, A; Perrotta, S; Ronzoni, L; Usala, E | 1 |
| Hori, A; Tanimoto, T; Tsubokura, M | 1 |
| Akard, LP | 1 |
| Porkka, K; Richter, J; Simonsson, B | 1 |
| Beyazit, Y; Haznedaroglu, IC; Kekilli, M | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Wierda, W | 1 |
| Annunziata, M; Breccia, M; Camera, A; Cavazzini, F; Gozzini, A; Isidori, A; Montefusco, E; Morra, E; Piccaluga, PP; Pregno, P; Santini, V; Specchia, G; Stagno, F; Usala, E; Visani, G | 1 |
| Camitta, B; Prestidge, T; Schultz, KR | 1 |
| Etienne, G; Huguet, F | 1 |
| Liu, D; Rafiyath, S; Wei, G | 1 |
| Ernst, T; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; Leitner, A; Lorentz, C; Müller, MC; Schenk, T; Schwindel, U | 1 |
| Cortés, JE; Holyoake, T; Kantarjian, H; Ranganathan, A; Saglio, G | 1 |
| Han, K; Kim, M; Kim, Y; Lee, SA; Lim, J | 1 |
| Hamšíková, E; Humlová, Z; Janatková, I; Klamová, H; Králíková, P; Malíčková, K; Roth, Z; Sterzl, I; Vonka, V | 1 |
| Alfonso, G; Alú, MF; Belli, C; Bianchini, M; Larripa, I | 1 |
| Cross, NC; Ernst, T; Hochhaus, A; La Rosée, P; Müller, MC | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Okimoto, RA; Van Etten, RA | 1 |
| Burchert, A; Neubauer, A | 1 |
| Chen, Y; Li, D; Li, S; Peng, C | 1 |
| Hobernicht, SL; Hunger, SP; Schweiger, B; Wang, M; Zeitler, P | 1 |
| Quintás-Cardama, A; Santos, FP | 1 |
| Bouvresse, S; Clérici, T; de Masson, A; Mahé, E; Saïag, P | 1 |
| Harnicar, S | 1 |
| Branford, S; Prime, J | 1 |
| Griffiths, EA; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Fujisawa, S; Fujita, H; Ishigatsubo, Y; Kanamori, H; Maruta, A; Motohashi, K; Numata, A; Sakai, R; Tachibana, T; Tanaka, M; Tomita, N | 1 |
| Pardanani, A | 1 |
| Angiolini, M | 1 |
| Hughes, TP; White, DL | 1 |
| Silver, RT | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Federico, V; Loglisci, G; Loglisci, MG; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Craddock, C; Novitzky-Basso, I | 1 |
| Drummond, M; Gallipoli, P; Holyoake, T; Irvine, D; Shepherd, P | 1 |
| Miura, M; Sawada, K; Takahashi, N | 1 |
| Ravandi, F | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, K; Kobayashi, Y; Miyawaki, S; Motoji, T; Nagai, T; Ohno, R; Okada, M; Sakamaki, H; Seriu, T; Taniwaki, M; Uoshima, N; Usui, N; Yamamoto, K | 1 |
| Liang, R; Rubin, BP; Schadendorf, D; Wallace, AR | 1 |
| Geoerger, B; Leblond, P | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Rosti, G; Soverini, S | 1 |
| Akin, C; DeRemer, DL; Ustun, C | 1 |
| Cortes, J; Kantarjian, H; Mathisen, MS; O'Brien, S; Ravandi, F; Thomas, D | 1 |
| Dinis, J; Fernandes, AR; Gromicho, M; Laires, A; Magalhães, M; Rodrigues, AS; Rueff, J; Tavares, P | 1 |
| Andrich, K; Dalhoff, C; Dreger, M; Fischer, JJ; Glinski, M; Graebner, OY; Koester, H; Kroll, F; Michaelis, S; Schrey, AK; Sefkow, M | 1 |
| Hiwase, DK; White, DL; Yeung, DT | 1 |
| Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
| Guo, L; He, L; Li, J; Xu, G; Yu, S | 1 |
| Abdool, A; Bruey, JM; Yeh, CH | 1 |
| Radich, JP | 1 |
| Hughes, TP; Moore, S; Parker, WT; Prime, JA; Schafranek, L; Tang, C; Watkins, DB; White, DL | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Engh, RA; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Porkka, K | 1 |
| Harada, H; Harada, Y; Imagawa, J; Kimura, A; Matsumoto, K; Morita, K; Tarutani, M; Yoshida, T | 1 |
| Alimena, G; Breccia, M; Cannella, L; Colafigli, G; De Cuia, MR; Loglisci, G; Nanni, M; Salaroli, A; Serrao, A | 1 |
| Brossart, P; Grünebach, F; Gutknecht, M; Rittig, SM; Salih, HR; Salih, J; Schwarzbich, MA | 1 |
| Guilhot, F; Roy, L; Tomowiak, C | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Bagadi, S; Das, B; Pany, A; Saikia, T | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
| Matsumura, I | 2 |
| Branford, S; Ho, M; Hughes, TP; Irwin, DL; Lawrence, RM; Parker, WT; Scott, HS | 1 |
| Ariaudo, A; Baietto, L; Cusato, J; D'Avolio, A; De Francia, S; Di Carlo, F; Di Perri, G; Fava, C; Saglio, G; Simiele, M | 1 |
| Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O | 1 |
| Kim, EJ; Zalupski, MM | 1 |
| Krusch, M; Salih, HR | 1 |
| Erben, P; Hanfstein, B; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Mueller, MC; Schenk, T | 1 |
| Bendit, I; de Barros Ferreira, P; Dorlhiac-Llacer, PE; Martins, TF; Nardinelli, L; Sanabani, SS; Seguro, F; Serpa, M | 1 |
| Bhatia, R; Chen, WY; Roth, M; Wang, Z; Yuan, H; Zhang, H | 1 |
| Kalaycio, M; Tiu, R | 1 |
| Reed, SD | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Rogers, G; Stein, K | 1 |
| Agarwal, MB; Baccarani, M; Bradley-Garelik, MB; Cortes, JE; Hochhaus, A; Ipiña, JJ; Junghanss, C; Kantarjian, HM; Kim, DW; Milone, JH; Nicolini, FE; Ogura, M; Pavlovsky, C; Robak, T; Shah, NP; Undurraga, MS; Van Droogenbroeck, J; Vellenga, E; Wang, J; Zhu, C | 1 |
| Cziraky, M; Davis, C; Hamdan, M; Hirji, I; Oliveria, SA; Yood, MU | 1 |
| Aoki, J; Hirashima, Y; Kakihana, K; Kobayashi, T; Ohashi, K; Sakamaki, H | 1 |
| Druker, BJ; Eide, CA; Hayward, R; Heidorn, S; Marais, R; Niculescu-Duvaz, I; O'Hare, T; Packer, LM; Rana, S; Rebocho, A; Springer, C; Zabriskie, MS | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Balci, TB; Karakus, S; Ozdogu, H; Sahin, FI | 1 |
| Alessandro, R; De Leo, G; Flugy, A; Garfield, SH; Kohn, EC; Mineo, M; Taverna, S | 1 |
| Branford, S; Ho, M; Hughes, TP; Parker, WT; Scott, HS | 1 |
| Hagihara, K; Hayashi, Y; Hino, M; Hirose, A; Katayama, T; Koh, H; Nakamae, H; Nakamae, M; Nakane, T; Nakao, Y; Terada, Y | 1 |
| Erba, HP; Pham, DC; Tai, S; Vu, H; Zaiden, R | 1 |
| Cantú-Rodríguez, O; García-Rodríguez, F; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, H; Jaime-Pérez, J | 1 |
| Coluccia, AM; De Leo, S; de Luca, E; De Matteis, S; Di Renzo, N; Dini, L; Maffia, M; Palamà, I; Passerini, CG; Reddiconto, G; Toto, C | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W | 1 |
| Dreosti, L; Jogessar, V; Louw, VJ; Moodley, D; Novitzky, N; Patel, M; Ruff, P; Schmidt, A; Willem, P | 1 |
| Abbott, BL | 1 |
| Auewarakul, CU; Thongnoppakhun, W; Wongboonma, W | 1 |
| Baccarani, M; Besson, N; Brümmendorf, TH; Cortes, JE; Countouriotis, A; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Zaritskey, A | 1 |
| Fukushima, N; Ichinohe, T; Kimura, S | 1 |
| Goulden, S; Stevens, A; Sutcliffe, F | 1 |
| Pfirrmann, M; Saussele, S | 1 |
| Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintas-Cardama, A | 1 |
| Wise, J | 1 |
| Atallah, E; Haddad, RY; Torgerson, SR | 1 |
| Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Mitra, D; Trask, PC | 1 |
| Boxer, SG; Levinson, NM | 1 |
| Koskela, H; Koskenvesa, P; Mustjoki, S; Porkka, K | 1 |
| Jootar, S | 1 |
| Berghausen, EM; Brandes, RP; Butrous, E; Butrous, G; Dabral, S; Dahal, BK; Ghofrani, HA; Grimminger, F; Pullamsetti, SS; Rosenkranz, S; Savai, R; Schermuly, RT; Seeger, W; Tretyn, A; Weissmann, N | 1 |
| Blake, SJ; Hughes, TP; Lyons, AB | 1 |
| Giles, F; Gjertsen, B; Labar, B; Mahon, FX; Rosti, G; Swords, R; Turkina, A | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Bryant, J; Clegg, A; Colquitt, JL; Cooper, K; Frampton, GK; Loveman, E | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Qin, YZ; Shi, HX | 1 |
| Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL | 1 |
| Antonescu, CR; Besmer, P; Bosbach, B; de Stanchina, E; Deshpande, S; Manova-Todorova, K; Moore, MA; Rossi, F; Scandura, JM; Shieh, JH; Sommer, G; Veach, DR | 1 |
| Kantarjian, H; Liu-Dumlao, T; O'Brien, S; Ravandi, F; Thomas, DA | 1 |
| Kanzaki, S; Kure, A; Okuno, K; Sano, H; Tamoto, N; Ueyama, J | 1 |
| Alvarez, S; Blanco, R; Bretones, G; Caraballo, JM; Cigudosa, JC; Delgado, MD; Ferrándiz, N; García-Alegria, E; Gómez-Casares, MT; León, J; López-Jorge, CE; Martín-Perez, J; Sánchez-Bailón, P; Vaqué, JP | 1 |
| Chen, L; Griffin, JD; Guérin, A; Ponce de Leon, D; Wu, EQ | 1 |
| Fava, C; Rege-Cambrin, G; Saglio, G | 1 |
| Dingermann, T; Marschalek, R; Zündorf, I | 1 |
| Airley, R | 1 |
| Kralj, E; Kristl, A; Pajič, T; Trontelj, J | 1 |
| Auberger, P; Aumann, K; Braun, S; Brummer, T; Daly, RJ; Halbach, S; Laßmann, S; Pahl, HL; Penninger, JM; Schramek, D; Schwemmers, S; Waller, CF; Werner, M; Wöhrle, FU; Zeiser, R | 1 |
| Birch, M; Flanagan, RJ; Handley, S; Ho, A; Ireland, R; Morgan, PE | 1 |
| Agarwal, A; Deininger, MW; Druker, BJ; Fleischman, AG; Loriaux, M; Luty, S; MacKenzie, R; Petersen, CL; Woltjer, RL | 1 |
| Appelbaum, FR; Deininger, M; Druker, BJ; Emanuel, P; Kamel-Reid, S; Kopecky, KJ; Larson, RA; Lipton, J; Malnassy, G; Paietta, E; Radich, JP; Stock, W; Tallman, M; Turner, AR; Wadleigh, M | 1 |
| Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
| Azam, M | 1 |
| Jabbour, E; Mathisen, MS; O'Brien, S | 1 |
| Cortes, J; Santos, FP | 1 |
| Bianchino, G; D'Arena, G; D'Auria, F; Deaglio, S; Del Vecchio, L; Gemei, M; Grieco, V; Guariglia, R; Luciano, L; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Statuto, T; Villani, O | 1 |
| Bowles, DW; Green, K; Thienelt, CD | 1 |
| Araki, E; Furukawa, N; Kawaguchi, T; Kikukawa, Y; Ono, K; Shimomura, T; Suzushima, H; Watanabe, Y | 1 |
| Dan, K; Inokuchi, K; Tamai, H; Yamaguchi, H | 1 |
| Abruzzese, E; Albano, F; Alimena, G; Annunziata, M; Breccia, M; Cambrin, GR; Castagnetti, F; Fanin, R; Fava, C; Gozzini, A; Latagliata, R; Luciano, L; Montefusco, E; Musto, P; Pane, F; Pregno, P; Rosti, G; Stagno, F; Tiribelli, M; Vigneri, P | 1 |
| Jabbour, E; Kantarjian, H | 1 |
| Hirase, C; Matsumura, I | 1 |
| Anderson, R; Ciani, O; Cooper, C; Crathorne, L; Garside, R; Hoyle, M; Jones-Hughes, T; Osipenko, L; Pavey, T; Rudin, C; Ukoumunne, O; Venkatachalam, M | 1 |
| Cortes, J | 1 |
| Jacobsen, PB; Jim, HS; Komrokji, R; Lancet, J; Lee, MR; Phillips, KM; Pinilla-Ibarz, J; Small, BJ; Sokol, L; Sotomayor, E; Sweet, K; Tinsley, S | 1 |
| Cerbón, MA; Coronel-Cruz, C; González-Sánchez, I; Lira-Rocha, A; Loza-Mejía, MA; Mendoza-Rodríguez, CA; Navarrete, A | 1 |
| Madrid, EM; Mahanty, S; Nash, TE | 1 |
| Marin, D | 2 |
| Auberger, P; Cassuto, JP; Cassuto, O; Dubois, A; Dufies, M; Ginet, C; Hamouda, A; Jacquel, A; Karsenti, JM; Legros, L; Lenain, P; Luciano, F; Puissant, A; Robert, G | 1 |
| Baxendale, IR; Deadman, BJ; Hopkin, MD; Ley, SV | 1 |
| Kamel-Reid, S; Kim, DD; Lee, H; Lipton, JH | 1 |
| Dolgin, E | 1 |
| Bellisola, G; Cinque, G; Gambacorti Passerini, C; Moratti, E; Redaelli, S; Silvestri, G; Sorio, C; Vezzalini, M; Wehbe, K | 1 |
| Barbany, G; Dybedal, I; Ehrencrona, H; Fioretos, T; Gedde-Dahl, T; Gjertsen, BT; Hernesniemi, S; Hjorth-Hansen, H; Hovland, R; Josefsen, D; Koskenvesa, P; Markevärn, B; Mustjoki, S; Olofsson, T; Olsson-Strömberg, U; Porkka, K; Rapakko, K; Richter, J; Simonsson, B; Stenke, L; Thunberg, S | 1 |
| Hu, JD; Huang, XJ; Jin, J; Li, JY; Liu, T; Meng, FY; Shen, ZX; Wang, JM; Wang, JX; Wu, DP | 1 |
| Simoneau, CA | 1 |
| Cetkovsky, P; Cmunt, E; Dusek, L; Dvorakova, D; Jurcek, T; Klamova, H; Machova Polakova, K; Mayer, J; Muzik, J; Racil, Z; Razga, F; Zackova, D | 1 |
| Bua, M; Clark, R; Gerrard, G; Goldman, J; Lucas, C; Marin, D; May, P; Milojkovic, D; Neelakantan, P; O'Brien, S; Paliompeis, C; Reid, A; Rezvani, K; Wang, L | 1 |
| Jabbour, EJ; Quintás-Cardama, A | 1 |
| Noronha, S; Sawyer, S | 1 |
| Koutna, I; Mayer, J; Potesil, D; Potesilova, M; Simara, P; Stejskal, S; Tesarova, L; Zdrahal, Z | 1 |
| Aung, T; Beutler, M; Cameron, S; Chapuy, B; Haase, D; Hupfeld, T; Koch, R; Larosee, P; Schrader, V; Truemper, L; Veltkamp, C; Wulf, GG | 1 |
| Boqué, C; Cabezón, M; Feliu, E; Fernández de Sevilla, A; Fernández, C; Grau, J; Marcé, S; Millá, F; Navarro, JT; Ribera, JM; Xicoy, B; Zamora, L | 1 |
| Costantini, A; Lasala, R; Rizzo, RC; Santoleri, F; Sorice, P | 1 |
| Antonescu, CR; Jain, S; Martz, J; Mosquera, JM; Popa, EC; Qin, L; Vahdat, LT | 1 |
| Gómez Casares, MT; León, LG | 1 |
| Chen, L; Griffin, JD; Guerin, A; Ionescu-Ittu, R; Luo, J; Macalalad, AR; Wu, EQ | 1 |
| Irvine, E; Williams, C | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Robert, C; Sibaud, V | 1 |
| Hu, JD; Huang, XJ; Shen, ZX; Wang, JX; Zhou, L | 1 |
| Borroni, G; Brazzelli, V; Grasso, V | 1 |
| Carrascosa, R; Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Steegmann, JL | 1 |
| Bell, J; Butt, NM; Clark, RE; De Soysa, L; Francis, S; Kaleel-Rahman, M; Knight, K; Lane, S; Lee, E; Lucas, C; O'Brien, D; Sadik, W; Salim, R; Seale, JR; Wang, L; Watmough, S | 1 |
| Borthakur, G; Cardenas-Turanzas, M; Cortes, J; Jabbour, E; Jain, P; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintás-Cardama, A; Ravandi, F; Romo, CG; Verstovsek, S | 1 |
| Erben, P; Hochhaus, A; Klag, T; La Rosée, P; Leitner, A; Martiat, P; Müller, MC; Saussele, S; Schenk, T | 1 |
| Adam, K; D'allard, D; Descarpentries, C; Dubreuil, P; Floquet, C; Fontenay, M; Frisan, E; Gay, J; Kosmider, O; Lacombe, C; Mayeux, P; Verdier, F | 1 |
| Kataoka, T; Kayukawa, S; Kusumoto, S; Narita, T; Yoshida, T | 1 |
| Costa, FF; De Souza, CA; Fachel, AA; Moreira, YB; Pagnano, KB; Silveira, RA; Verjovski-Almeida, S | 1 |
| Onoda, M; Shono, K; Togasaki-Yoshimoto, E; Yokota, A | 1 |
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Pregno, P; Riccomagno, P | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Goldman, JM; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Pane, F; Radich, JP; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, R; Simonsson, B; Soverini, S; Steegmann, JL | 1 |
| Ge, Z; Hong, M; Li, JY; Pan, LQ; Qian, SX; Song, P; Tian, T; Yu, H; Zhang, SJ; Zhu, Y | 1 |
| Baldwin, AS; Christopherson, RI; Cooper, MJ; Cox, NJ; Dewar, BJ; Duncan, JS; Frye, SV; Ghose Roy, S; Graves, LM; Jin, J; Johnson, GL; Jones, LS; Kuan, PF; Nguyen, TA; Richards, KL; Smalley, DM; Whittle, MC; Zimmerman, EI | 1 |
| Burger, JA; Challagundla, P; Champlin, RE; Cortes, JE; Estrov, Z; Faderl, S; Ferrajoli, A; Garris, R; Huang, X; Jorgensen, JL; Kantarjian, HM; Kebriaei, P; Luthra, R; O'Brien, S; Ravandi, F; Thomas, DA; Wang, SA; Wen, S | 1 |
| Chen, LT; Chen, TS; Chiang, NJ; Hsueh, YS; Ko, CH; Li, CF; Lin, CL; Shan, YS; Shih, NY; Wang, LM; Yen, CC | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Klamová, H | 1 |
| Borthakur, G; Burger, JA; Cortes, JE; Falchi, L; Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Luthra, R; O'Brien, S; Quintás-Cardama, A; Ravandi-Kashani, F; Verma, D; Verstovsek, S; Wang, X | 1 |
| Saglio, G; Savona, MR | 1 |
| Clark, R; Drummond, M; Gallipoli, P; Heaney, N; Holyoake, TL; Hughes, T; McLintock, L; Michor, F; Nicolini, FE; Paul, J; Stobo, J; Tighe, J; Wilson, G | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Druker, BJ; Eide, CA; O'Hare, T; Shukron, O; Vainstein, V | 1 |
| Miura, M; Takahashi, N | 1 |
| Gastl, G; Kastner, U; Lion, T; Mitterbauer-Hohendanner, G; Seger, C; Webersinke, G | 1 |
| Chirovsky, DR; Davis, CC; Goren, A; Gupta, S; Hirji, I; Moadel, AB; Olavarria, E; Victor, TW | 1 |
| Eadie, LN; Hughes, TP; White, DL | 1 |
| Ayyagari, R; Chen, L; Reichmann, WM; Signorovitch, J; Wu, EQ | 1 |
| Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Bonkovsky, HL; Hwang, SI; Lee, JG; McKinney, KQ; Mougeot, JL | 1 |
| Ando, T; Kimura, S; Kojima, K | 1 |
| Atanackovic, D; Goekkurt, E; Harbaum, L; Marx, A; Schafhausen, P | 1 |
| Bradley-Garelik, MB; Chuah, CT; Kim, DW; Nakamae, H; Shen, ZX | 1 |
| Arai, H; Handa, T; Iso, H; Mitani, K; Nagasawa, F; Nakamura, Y; Sasaki, K; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Baccarani, M; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; Kim, DW; Mayer, J; Mohamed, H; Pavlovsky, C; Saglio, G; Shah, NP; Steegmann, JL; Wildgust, M | 1 |
| Boiso Moreno, S; Carlsson, B; Gréen, H; Jönsson, JI; Skoglund, K; Vikingsson, S | 1 |
| Abruzzo, L; Alattar, ML; Borthakur, G; Champlin, R; Cortes, JE; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, HM; Luthra, R; O'Brien, S; Ohanian, M; Pierce, S; Quintas-Cardama, A; Ravandi, F; Trinh, LX; Verstovsek, S | 1 |
| Adams, E; Chen, H; Chopra, S; Van Schepdael, A; Wang, X | 1 |
| Akiyama, H; Fujisawa, S; Ishida, Y; Ishizawa, K; Matsue, K; Nakamae, H; Ogura, M; Onishi, S; Takamatsu, Y; Tanimoto, M; Taniwaki, M; Usuki, K; Utsunomiya, A | 1 |
| Iijima, K; Ishibashi, T; Kiyokawa, N; Kobayashi, K; Mori, T; Okita, H; Osumi, T; Saito, M; Shimizu, T; Tomita, O | 1 |
| Inokuchi, K; Nakayama, K | 1 |
| Irie, T; Izumiyama, K; Kato, T; Meguro, T; Mori, A; Morioka, M; Musashi, M; Saga, A; Saito, M; Tanaka, M; Tanino, M | 1 |
| Bhojwani, D; Campana, D; Cheng, C; Choi, JK; Coustan-Smith, E; Howard, SC; Inaba, H; Jacobsen, J; Jeha, S; Metzger, ML; Pei, D; Pui, CH; Raimondi, S; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Shurtleff, SA | 1 |
| Anderson, KR; Chambers, CR; Cusano, F; Lam, N; Savoie, ML; Sheikh, N; Yau, PS | 1 |
| Brümmendorf, TH; Cortes, JE; Cunningham, M; Guilhot, F; Healey, D; Hochhaus, A; Kantarjian, HM; le Coutre, P; Mohamed, H; Rousselot, P; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Hatta, Y | 1 |
| McElligott, F; O'Marcaigh, A; O'Rafferty, C; Smith, O; Storey, L | 1 |
| Abraham, J; Aslam, MI; Druker, BJ; Keller, C; Mansoor, A; Tyner, JW | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Brazzelli, V; Croci, G; Grasso, V; Vassallo, C | 1 |
| Gong, YP; Guo, Y; Lin, J; Shi, R | 1 |
| Dalm, VA; Dik, WA; Hirankarn, N; Paridaens, D; van den Bosch, WA; van Hagen, PM; Virakul, S | 1 |
| Bhatia, R; Chen, W; Chu, S; Liu, Z; Roth, M; Wang, J; Wang, Z; Wu, X; Yuan, H; Yuan, YC | 1 |
| Alfonso, A; Botana, LM; Tobío, A | 1 |
| Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Gjertsen, BT; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lotfi, K; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Remes, K; Richter, J; Simonsson, B; Söderlund, S; Stenke, L; Suominen, M | 1 |
| Acin, Y; Adenis, A; Bertucci, F; Blay, JY; Blésius, A; Bompas, E; Bouché, O; Bui-Nguyen, B; Bulusu, VR; Chaigneau, L; Domont, J; Dubreuil, P; Hermine, O; Isambert, N; Le Cesne, A; Mansfield, CD; Moussy, A; Ray-Coquard, I; Van Tine, BA | 1 |
| Ahmad, S; Anderson, DJ; Arpin, CC; Baron, R; Deininger, MW; Eiring, AM; Engar, AJ; Gunning, PT; Heaton, WL; Khorashad, JS; Kraft, IL; Mason, CC; Moriggl, R; O'Hare, T; Page, BDG; Pomicter, AD; Resetca, D; Reynolds, KR; Senina, A; Tantravahi, SK; Todic, A; Vellore, NA; Wilson, DJ; Zabriskie, MS; Zhang, TY | 1 |
| Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V | 1 |
| Cho, EH; Chung, Y; Eom, HS; Kong, SY; Lee, H; Park, S; Shim, H | 1 |
| Branford, S; Cortes, J; Gonen, M; Hughes, T; Michor, F; Olshen, A; Quintás-Cardama, A; Tang, M | 1 |
| Chen, M; Jiang, X; Lin, H; Lorenzi, MV; Rothe, K; Woolfson, A | 1 |
| Takahashi, N | 1 |
| Agopian, J; Bertucci, F; Chauvot de Beauchêne, I; De Sepulveda, P; Dubreuil, P; Fouet, B; Fournier, B; Mescam-Mancini, L; Panel, N; Tchertanov, L; Tisserand, JC; Vita, M | 1 |
| Gambacorti-Passerini, C; Piazza, R | 1 |
| Blalock, SJ; Earnshaw, SR; Fang, G; Happe, LE; Richards, KL; Walko, CM; Ward, MA | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Whiteley, J | 1 |
| Zsila, F | 1 |
| Fujisawa, S; Hatta, Y; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C | 1 |
| Cortes, J; Malhotra, R; Mauro, M; Saglio, G; Steegmann, JL; Ukropec, JA; Wallis, NT | 1 |
| Bennuru, S; Dolan, MA; Nutman, TB; O'Connell, EM; Steel, C | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Diverio, D; Latagliata, R; Mancini, M; Molica, M; Tafuri, A | 1 |
| Alvarez-Larrán, A; Bautista, G; Bobillo, S; Boqué, C; Cuevas, B; de Las Heras, N; Deben, G; Fernandez, A; García Garay, Mdel C; García-Gutiérrez, V; Giraldo, P; Guinea, JM; Iglesias Pérez, A; Lopez Lorenzo, JL; Maestro, B; Martin Mateos, ML; Martinez-Trillos, A; Mata, I; Ortega, F; Portero, A; Ramirez Sánchez, MJ; Romero, E; Romo Collado, A; Ruiz, C; Sebrango, A; Steegmann, JL; Tallón, J; Valencia, S | 1 |
| Wolf, D | 1 |
| Collassanti, MDS; Covas, DT; de Castro, FA; de Oliveira, GLV; de Souza, AM; Ferreira, AF; Hamerschlak, N; Kashima, S; Tognon, R; Zanichelli, MA | 1 |
| Deng, P; Hantschel, O; Kuriyan, J; Lorenz, S; Superti-Furga, G | 1 |
| Nishida, T; Tsukazaki, K | 1 |
| Dahl, J; Jabbour, EJ; Mace, ML | 1 |
| Cabezón, M; Cortés, M; Feliu, E; Grau, J; Marcé, S; Millá, F; Zamora, L | 1 |
| Fujii, S; Miura, I; Tanaka, H | 1 |
| Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G | 1 |
| Ross, DM | 1 |
| Choi, YG; Kim, JA; Lee, J; Nam, YJ; Yim, E | 1 |
| Bracha, S; Goodall, CP; Helfand, SC; Löhr, CV; Marley, K; Milovancev, M | 1 |
| Capitani, S; Celeghini, C; Evangelisti, C; Marisi, G; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Ulivi, P; Ultimo, S; Zauli, G | 1 |
| Audebert, S; Baudelet, E; Betzi, S; Casteran, N; Combes, S; De Sepulveda, P; Dubreuil, P; Gros, L; Hajem, B; Hammam, K; Humbert, M; Letard, S; Lopez, S; Lugari, A; Mansfield, C; Morelli, X; Moussy, A; Rebuffet, E; Saez-Ayala, M | 1 |
| Eskazan, AE | 1 |
| Gettler, B; Williams, SK; Zabonick, J; Zakhari, JS | 1 |
| Calabrò, C; Gadaleta, CD; Laforgia, M; Marech, I; Nardulli, P; Ranieri, G | 1 |
| Bakhshi, S; Pushpam, D | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Boucher, J; Harms, M; Maurer, S | 1 |
| Cantonetti, M; Cattel, F; Celeste, MG; Colasanto, I; Costantini, A; de Rosa, C; Di Biagio, K; Federici, F; Franceschini, L; Frazzetto, A; La Barba, G; Lanzillo, R; Luciano, L; Monteverde, M; Musicco, F; Pane, F; Pasquazi, A; Ranucci, E; Rizzo, M; Rossi, C; Santoleri, F; Scaldaferri, M; Scortechini, AR; Torquati, G; Vozza, A | 1 |
| Dalal, H; Damodar, S; Gowda, DA; H, K; Subramanian, S; V P, S; Vyas, N | 1 |
| Cao, H; Jia, X; Lee, JC; Liu, X; Lu, X; Pang, Y; Shen, Y; Tu, L; Wang, Y | 1 |
| Bauer, S; Berhanu, G; Brandt, U; Gelderblom, H; Grignani, G; Heinrich, MC; Italiano, A; Pantaleo, MA; Reichardt, P; Reyners, AKL; Schöffski, P; Stark, D; Stefanelli, T; Valverde, C | 1 |
166 review(s) available for thiazoles and imatinib mesylate
| Article | Year |
|---|---|
BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2005 |
Chronic myelogenous leukemia.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Stem Cell Transplantation; Thiazoles; Translocation, Genetic | 2005 |
Targeted CML therapy: controlling drug resistance, seeking cure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[Novel inhibitors of Bcr-Abl].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Panobinostat; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyridones; Pyrimidines; Thiazoles | 2006 |
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
[Molecular targeting therapy for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
What is new in chronic myeloid leukaemia?
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Splenomegaly; Thiazoles | 2007 |
Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Everolimus; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Indoles; Niacinamide; Oligonucleotides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sirolimus; Staurosporine; Sunitinib; Thiazoles | 2006 |
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nurse's Role; Nursing Assessment; Oncology Nursing; Philadelphia Chromosome; Piperazines; Practice Guidelines as Topic; Primary Health Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Thiazoles; Treatment Outcome | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
[Novel anti-CML agents beyond imatinib].
Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Adult; Benzamides; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Thiazoles; Treatment Outcome | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
What's blasting off in CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Monitoring; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Pyrimidines; Risk Factors; Thiazoles | 2007 |
Characterization of cancer stem cells in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2007 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
New strategies in controlling drug resistance.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
New strategies in controlling drug resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Chemical; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiazoles | 2007 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
[Research advance on molecular genetics of CML blast crisis].
Topics: Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2008 |
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Overcoming kinase resistance in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Therapy options in imatinib failures.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2008 |
Management of patients with resistant or refractory chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome | 2008 |
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2008 |
Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges.
Topics: Animals; Benzamides; Chronic Disease; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Immune System Diseases; Inflammation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Nilotinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Chemical; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Fibrosis; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Scleroderma, Systemic; Skin; Sulfonamides; Thiazoles | 2008 |
[Management of acute lymphoblastic leukemia].
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Molecular Diagnostic Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Thiazoles | 2008 |
[Management of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
Targeted drugs in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; src-Family Kinases; Thiazoles | 2008 |
[Chronic myeloid leukemia 2008].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2008 |
Imatinib and its successors--how modern chemistry has changed drug development.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Discovery; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2009 |
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Failure | 2009 |
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antirheumatic Agents; Benzamides; Cyclophosphamide; Dasatinib; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interleukin-13; Lung Diseases, Interstitial; Mycophenolic Acid; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Respiratory Function Tests; Scleroderma, Systemic; Thiazoles; Treatment Outcome | 2009 |
First-line therapy for chronic myeloid leukemia: Past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Cyclophosphamide; Dasatinib; Dexamethasone; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Thiazoles; Translocation, Genetic; Vincristine | 2009 |
Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Treatment selection after imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Utilization; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Genetic; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Failure | 2009 |
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome | 2009 |
Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation Conditioning; Treatment Outcome | 2009 |
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Costs and Cost Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles; Treatment Outcome | 2009 |
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Response dynamics in chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.
Topics: Administration, Oral; Benzamides; Carcinoma; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Dasatinib; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Outcome | 2009 |
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].
Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2009 |
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
New insights into small-molecule inhibitors of Bcr-Abl.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2011 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
[Clinical use of tyrosine kinase inhibitors for treatment of myeloid leukemias].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Europe; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2009 |
[Clinical progress in chronic myelogenous leukemia].
Topics: Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dasatinib; Drug Discovery; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Comorbidity; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Mutation; Piperazines; Prognosis; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2010 |
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib: is it all in the dose?
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles | 2006 |
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mice; Multicenter Studies as Topic; Mutation; Piperazines; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2007 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
First-line therapy for chronic myeloid leukemia: new horizons and an update.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Dasatinib; Disease Management; Drug Administration Schedule; Drug Eruptions; Humans; Hypercholesterolemia; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2010 |
[Development of ABL tyrosine kinase inhibitors].
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2010 |
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2011 |
Allosteric inhibition of BCR-ABL.
Topics: Allosteric Regulation; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Thiazoles; Transplantation, Homologous | 2010 |
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Topics: Benzamides; Clinical Trials as Topic; Congresses as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2011 |
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Clinical Trials as Topic; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles | 2011 |
New drugs for chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles | 2011 |
Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.
Topics: Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Chronic myelogenous leukemia: monitoring response to therapy.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Interpretation of cytogenetic and molecular results in patients treated for CML.
Topics: Benzamides; Cytogenetics; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis.
Topics: Benzamides; Dasatinib; Drug Discovery; Imatinib Mesylate; Inflammation; Models, Molecular; Molecular Conformation; Neoplasms; Patents as Topic; Phosphotransferases; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2011 |
Predicting the response of CML patients to tyrosine kinase inhibitor therapy.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2011 |
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous | 2011 |
Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transport Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Topics: Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Publication Bias; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2012 |
[TKI therapy for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2011 |
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Sunitinib; Thiazoles | 2011 |
Effects of BCR-ABL inhibitors on anti-tumor immunity.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2011 |
Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Myeloproliferative neoplasms (including chronic myeloid leukemia)].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles | 2012 |
Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2012 |
Clinical trials in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2012 |
Chronic myelogenous leukemia for primary care physicians.
Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
[Current therapy of chronic myeloid leukemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Thiazoles; Treatment Outcome | 2012 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance; Drug Therapy, Combination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Thiazoles; Treatment Outcome; United Kingdom | 2012 |
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors | 2012 |
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Neoplasm, Residual; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2012 |
Chronic myeloid leukemia: state of the art in 2012.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Leukemia: A highly malignant disease].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2012 |
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2012 |
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Thiazoles | 2012 |
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Nitriles; Piperazines; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2012 |
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2013 |
Treating chronic myeloid leukemia: improving management through understanding of the patient experience.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Style; Patient Compliance; Patient Education as Topic; Piperazines; Pyrimidines; Quality of Life; Thiazoles | 2013 |
Management of the new patient with CML in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Topics: Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Skin; Thiazoles | 2013 |
Management options for refractory chronic myeloid leukemia: considerations for the elderly.
Topics: Age Factors; Aged; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Treatment Outcome | 2013 |
[Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2013 |
Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2013 |
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Current diagnostic requirements in chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Guideline Adherence; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; Thiazoles; Treatment Outcome | 2013 |
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Ever-advancing chronic myeloid leukemia treatment.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2014 |
[Chronic myeloid leukemia: up-to-date management].
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Discovery; Drug Monitoring; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Molecular Targeted Therapy; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
[Acute lymphoblastic leukemia].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Humans; Imatinib Mesylate; Methotrexate; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult | 2014 |
Tyrosine kinase inhibitors: muco-cutaneous side effects at the microscope.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Dasatinib; Exanthema; Humans; Imatinib Mesylate; Microscopy, Electron; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
[Treatment of chronic myeloid leukemia in chronic phase].
Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Translocation, Genetic | 2014 |
[Management of advanced stage chronic myeloid leukemia].
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Progression; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2014 |
How I treat newly diagnosed chronic myeloid leukemia in 2015.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2015 |
Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Topics: Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2015 |
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; Disease Progression; Gabexate; Guanidines; Humans; Imatinib Mesylate; Immune System; Mast Cells; Neovascularization, Pathologic; NF-kappa B; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Stomach Neoplasms; Thiazoles; Tryptases | 2015 |
An evaluation of masitinib for treating systemic mastocytosis.
Topics: Benzamides; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles | 2019 |
Paediatric chronic myeloid leukaemia: Is it really a different disease?
Topics: Antineoplastic Agents; Child; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pediatrics; Pyrimidines; Thiazoles | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
The colorful versatility of adipocytes: white-to-brown transdifferentiation and its therapeutic potential in humans.
Topics: Acetanilides; Adipocytes, Beige; Adipocytes, Brown; Adipocytes, White; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Lineage; Cell Transdifferentiation; Diabetes Mellitus; Drugs, Investigational; Energy Metabolism; Humans; Imatinib Mesylate; Obesity; Roscovitine; Thermogenesis; Thiazoles | 2021 |
56 trial(s) available for thiazoles and imatinib mesylate
| Article | Year |
|---|---|
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neutropenia; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Thiazoles; Treatment Failure | 2007 |
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Topics: Administration, Oral; Adult; Aged; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recovery of Function; src-Family Kinases; Thiazoles | 2007 |
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Topics: Benzamides; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2007 |
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Drug Resistance; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2007 |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Codon; Dasatinib; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Structure-Activity Relationship; Thiazoles | 2007 |
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Cytogenetics; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Time Factors | 2007 |
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Topics: Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Thiazoles | 2007 |
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pleural Effusion; Pyrimidines; Radiography; Risk Factors; Thiazoles; Treatment Failure | 2007 |
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Failure | 2008 |
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure | 2008 |
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2008 |
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hemorrhagic Disorders; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Platelet Count; Pyrimidines; Risk Factors; Thiazoles; Withholding Treatment; Young Adult | 2009 |
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult | 2009 |
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Genes, abl; Heart Diseases; Hematologic Diseases; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2009 |
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cross-Over Studies; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Withholding Treatment | 2009 |
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2009 |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2009 |
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; src-Family Kinases; Thiazoles; Young Adult | 2010 |
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or int
Topics: Benzamides; Cytogenetic Analysis; Dasatinib; Drug Administration Schedule; Drug Resistance; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; International Agencies; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2010 |
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Treatment Outcome | 2010 |
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2011 |
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous | 2012 |
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Age of Onset; Algorithms; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; DNA Mutational Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2012 |
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemokines; Cytokines; Dasatinib; Female; Humans; Imatinib Mesylate; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2012 |
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Probability; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2012 |
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Topics: Adult; Aged; Algorithms; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quinolines; Thiazoles; Treatment Failure; Young Adult | 2012 |
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
[Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
Topics: Acebutolol; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome | 2013 |
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.
Topics: Animals; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription Factors | 2013 |
[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles | 2013 |
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thiazoles | 2013 |
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Topics: Benzamides; Cell Cycle; Dasatinib; Drug Substitution; Drug Synergism; Follow-Up Studies; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pulse Therapy, Drug; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Asian People; Benzamides; Dasatinib; DNA Mutational Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2014 |
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Time; Treatment Outcome | 2014 |
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; Survival Analysis; Thiazoles | 2015 |
Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Thiazoles; Treatment Failure | 2014 |
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Treatment Outcome; Young Adult | 2014 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
Topics: Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Thiazoles; Treatment Outcome | 2022 |
350 other study(ies) available for thiazoles and imatinib mesylate
| Article | Year |
|---|---|
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Topics: Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; bcl-X Protein; Benzamides; Blotting, Western; Cell Line; Cell Line, Tumor; Coloring Agents; Cytochromes c; DNA-Binding Proteins; DNA, Complementary; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flavoproteins; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Membrane Potentials; Membrane Proteins; Milk Proteins; Mitochondria; Mutation; Piperazines; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; src-Family Kinases; STAT5 Transcription Factor; Tetrazolium Salts; Thiazoles; Trans-Activators; Transfection; Up-Regulation | 2004 |
Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Pyrimidines; Thiazoles | 2004 |
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Cell Line; Clinical Trials, Phase I as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutation; Piperazines; Protein Conformation; Pyrimidines; Thiazoles; Transfection | 2004 |
New generation leukaemia drugs are on their way.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2004 |
Abl tyrosine kinase promotes dendrogenesis by inducing actin cytoskeletal rearrangements in cooperation with Rho family small GTPases in hippocampal neurons.
Topics: Actin Cytoskeleton; Actins; Amides; Animals; Axons; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; cdc42 GTP-Binding Protein; Cells, Cultured; Cytoskeleton; Dendrites; Hippocampus; Imatinib Mesylate; Microtubule-Associated Proteins; Neurons; Piperazines; Proto-Oncogene Proteins c-abl; Pyridines; Pyrimidines; rac1 GTP-Binding Protein; Rats; rho GTP-Binding Proteins; Signal Transduction; Thiazoles; Thiazolidines | 2004 |
Oral BMS-354825 rescues Gleevec-resistant CML.
Topics: Administration, Oral; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
Two new agents effective in Gleevec-resistant CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
Anglo-Swedish Medicinal Chemistry - second symposium.
Topics: Animals; Benzamides; Chemistry, Pharmaceutical; Diabetes Mellitus, Type 2; Enzyme Activators; Glucokinase; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1; Societies, Scientific; src-Family Kinases; Sweden; Thiazoles; United Kingdom | 2005 |
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2005 |
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genetic Vectors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunoblotting; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Phosphotyrosine; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Stem Cells; Thiazoles; Time Factors | 2005 |
Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Carcinoma; Caspase 3; Caspase 7; Caspases; Cell Proliferation; Collagen; Drug Combinations; Fluorescent Antibody Technique; Genes, Reporter; Humans; Imatinib Mesylate; Immunoprecipitation; Laminin; Luciferases; Microscopy, Confocal; Oligonucleotide Array Sequence Analysis; Piperazines; Proteoglycans; Pyrimidines; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine; Thyroid Neoplasms; Transfection; Tumor Cells, Cultured | 2006 |
Loss of response to imatinib: mechanisms and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Failure | 2005 |
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Topics: Amino Acid Substitution; Animals; Benzamides; Cell Growth Processes; Cell Survival; CHO Cells; Cricetinae; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Isoenzymes; MAP Kinase Signaling System; Mice; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Topics: Aurora Kinases; Benzamides; Catalytic Domain; Crystallography; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2006 |
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Topics: Animals; Benzamides; Binding Sites; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Ligands; Mastocytosis, Systemic; Mice; Models, Molecular; Mutation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2006 |
Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib).
Topics: Animals; Aorta; Benzamides; Cell Line; Dasatinib; Imatinib Mesylate; Kinetics; Muscle, Smooth, Vascular; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Receptors, Platelet-Derived Growth Factor; Thiazoles | 2006 |
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Dosage; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; RNA, Neoplasm; Thiazoles | 2006 |
New assignments for multitasking signal transduction inhibitors.
Topics: Animals; Benzamides; Cell Line; Dasatinib; Imatinib Mesylate; Muscle, Smooth, Vascular; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Thiazoles | 2006 |
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Topics: Animals; Benzamides; Blast Crisis; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Kinase inhibitors in chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles | 2006 |
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.
Topics: Animals; Benzamides; Crystallography, X-Ray; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Imatinib Mesylate; Models, Molecular; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2006 |
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Screening Assays, Antitumor; Ethylnitrosourea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutagens; Piperazines; Point Mutation; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2006 |
Circumventing resistance to kinase-inhibitor therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Panniculitis; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Tyrosine kinase inhibitors: the next generation.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2006 |
Dasatinib in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Glivec and beyond.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2006 |
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured; Vorinostat | 2006 |
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Burkitt Lymphoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Topics: Aniline Compounds; Animals; Benzamides; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; K562 Cells; Mice; Mice, Nude; Models, Molecular; Mutation; Neoplasms; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; src-Family Kinases; Survival Analysis; Thiazoles; U937 Cells; Xenograft Model Antitumor Assays | 2006 |
Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Dasatinib; DNA Damage; DNA Repair; Enzyme Inhibitors; Gene Expression Regulation; Humans; Imatinib Mesylate; K562 Cells; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-abl; Oncogenes; Piperazines; Pyrimidines; RNA, Small Interfering; Thiazoles | 2007 |
Dasatinib (Sprycel) for CML and Ph + ALL.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Topics: Adolescent; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Dasatinib is effective in imatinib-resistant CML.
Topics: Benzamides; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; United Kingdom | 2007 |
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells; Thiazoles; Treatment Outcome | 2007 |
Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Thiazoles; Transplantation Conditioning; Treatment Outcome | 2007 |
Drugs offer new hope for patients with CML who are resistant to imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Patient Education as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2007 |
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine | 2007 |
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Topics: Animals; Benzamides; Blast Crisis; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Propylene Glycols; Protein Phosphatase 2; Pyrimidines; Signal Transduction; Sphingosine; Thiazoles; Time Factors; Tumor Cells, Cultured | 2007 |
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Topics: Benzamides; Dasatinib; Discoidin Domain Receptor 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinone Reductases; Receptor Protein-Tyrosine Kinases; Thiazoles | 2007 |
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
A new case with rare e6a2 BCR-ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation, Missense; Piperazines; Pyrimidines; RNA, Neoplasm; Thiazoles | 2008 |
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Topics: Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 4; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Translocation, Genetic | 2007 |
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2007 |
Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chimerism; Cord Blood Stem Cell Transplantation; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Thiazoles; Time Factors | 2007 |
Imatinib in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia: a viewpoint by Joseph Brandwein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous | 2007 |
Chronic myeloid leukemia. Introduction.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Leukemia. Q&A highlights.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pyrimidines; Thiazoles | 2007 |
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Thiazoles | 2008 |
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Blast Crisis; Caspase 3; Cell Death; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2008 |
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Topics: Adult; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Cycle; Cell Proliferation; Cells, Cultured; Chromones; Colony-Forming Units Assay; Dasatinib; DNA Primers; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thiazoles; Transfection | 2008 |
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Topics: Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2008 |
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
Topics: Animals; Benzamides; Cell Line; Coculture Techniques; Dasatinib; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Imatinib Mesylate; Interleukin-3; Janus Kinase 2; Mice; Mitogen-Activated Protein Kinase Kinases; Models, Animal; Mutation, Missense; Paracrine Communication; Piperazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2008 |
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration | 2008 |
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Death; Cell Survival; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Genes, abl; Humans; I-kappa B Kinase; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transfection; Tumor Cells, Cultured | 2008 |
Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Complications; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2008 |
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; DNA Damage; DNA Repair; Fibroblasts; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kinetics; Leukocytes, Mononuclear; Mice; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2008 |
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Survival; Dasatinib; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Experimental; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured | 2008 |
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Chemistry, Pharmaceutical; Dasatinib; Drug Design; Enzyme Inhibitors; Humans; Imatinib Mesylate; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Piperazines; Protein Conformation; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2008 |
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Point Mutation; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Insufficiency; Thiazoles | 2008 |
Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Topics: Adult; Benzamides; Dasatinib; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retinal Diseases; Thiazoles | 2008 |
Sequential tyrosine kinase inhibitor therapy: sustained disease remission in Philadelphia-positive erythroleukaemia.
Topics: Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Isolated central nervous system lymphoid blast crisis in chronic myeloid leukaemia in major molecular remission.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Dasatinib; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Pyrimidines; Remission Induction; T-Lymphocytes; Thiazoles | 2008 |
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Temperature; Thiazoles; Tumor Cells, Cultured | 2008 |
Disease progression in some cancers may be due to low blood levels of targeted therapies.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance.
Topics: Adolescent; Adult; Aged; Alternative Splicing; Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Genes, abl; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Cell Separation; Dasatinib; Dogs; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles | 2008 |
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
Topics: Benzamides; Dasatinib; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Erythroblastic, Acute; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Substrate Specificity; Thiazoles | 2008 |
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2008 |
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Thiazoles | 2008 |
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles | 2008 |
Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Poly(ADP-ribose) Polymerases; Pyrimidines; Signal Transduction; Thiazoles | 2008 |
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Renal Insufficiency; Thiazoles | 2009 |
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Topics: Benzamides; Bone Marrow; Cell Death; Cell Line, Tumor; Culture Media, Conditioned; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; STAT3 Transcription Factor; Thiazoles | 2008 |
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Topics: Adenosine Triphosphate; Benzamides; Cell Line; Cloning, Molecular; Collagen; Dasatinib; Discoidin Domain Receptor 1; Discoidin Domain Receptors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structural Homology, Protein; Thiazoles | 2008 |
Dasatinib-induced restoration of donor chimerism in BCR-ABL1-positive ALL after failure of imatinib therapy and allo-SCT.
Topics: Adolescent; Benzamides; Combined Modality Therapy; Dasatinib; Fatal Outcome; Genes, abl; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation Chimera | 2009 |
In vitro anti-leukaemia activity of sphingosine kinase inhibitor.
Topics: Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors | 2009 |
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2009 |
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
Topics: Benzamides; Chromosomes, Human, Pair 7; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Dasatinib induces a response in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blood Cell Count; Dasatinib; Female; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Jejunal Diseases; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Rituximab; src-Family Kinases; Thiazoles; Tomography, X-Ray Computed; Vidarabine | 2009 |
Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Autologous | 2009 |
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
Topics: Antineoplastic Agents; Benzamides; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Quinone Reductases; Structure-Activity Relationship; Thiazoles | 2009 |
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.
Topics: Benzamides; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dasatinib; Diclofenac; Enzyme Activation; Enzyme Inhibitors; Glutathione; Humans; Imatinib Mesylate; K562 Cells; Microsomes, Liver; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spectrometry, Mass, Electrospray Ionization; Thiazoles | 2009 |
Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Topics: Acetylation; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Histones; Humans; Imatinib Mesylate; Models, Molecular; Mutation; Phthalic Acids; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiophenes | 2009 |
Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma.
Topics: Animals; Benzamides; Chromatography, Liquid; Dasatinib; Imatinib Mesylate; Linear Models; Mice; Piperazines; Pyrimidines; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2009 |
The toxicities of modern targeted therapies: learning from the price of progress.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; ErbB Receptors; Hemorrhage; Humans; Imatinib Mesylate; Interdisciplinary Communication; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Sirolimus; Skin; Thiazoles; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzamides; Calcium; Cell Death; Cell Line, Tumor; Chloroquine; Dasatinib; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Mice; Mice, Inbred C3H; Microtubule-Associated Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; Thiazoles; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2009 |
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2009 |
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Benzamides; Caspases; Cell Growth Processes; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myeloid; Mutation; Oncogene Protein v-akt; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Pyrimidines; STAT3 Transcription Factor; Stem Cell Factor; Thiazoles | 2009 |
Dasatinib induces complete cytogenetic response and loss of F359C in an imatinib resistant chronic myelocytic leukemia patient.
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Melanoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tetrazolium Salts; Thiazoles | 2009 |
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles; Time Factors; Young Adult | 2009 |
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Topics: Benzamides; Blood Coagulation; Blood Platelet Disorders; Dasatinib; Health; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet Aggregation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Efficacy of dasatinib in conjunction with alpha-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Transplantation, Autologous | 2009 |
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Chronic myelogenous leukaemia market.
Topics: Benzamides; Dasatinib; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Piperazines; Pyrimidines; Thiazoles | 2009 |
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzamides; Blood Platelets; Dasatinib; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Middle Aged; Piperazines; Platelet Activation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hospitals, Public; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Expectancy; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Spain; Survival Rate; Thiazoles | 2009 |
Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Delivery, Obstetric; Female; Humans; Imatinib Mesylate; Interferons; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Thiazoles | 2009 |
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles | 2009 |
Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment.
Topics: Benzamides; Cell Line, Tumor; Chondrosarcoma; Dasatinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imatinib Mesylate; Jurkat Cells; MAP Kinase Signaling System; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; raf Kinases; ras Proteins; src-Family Kinases; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2009 |
Optimizing first-line therapy for patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
New directions in the treatment of imatinib failure and/or resistance.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2009 |
In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Size; Cell Survival; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tetrazolium Salts; Thiazoles | 2010 |
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; DNA Mismatch Repair; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Humans; Imatinib Mesylate; Melanoma; Models, Molecular; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2009 |
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Topics: Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Biphenotypic, Acute; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Sequence Deletion; Thiazoles | 2009 |
The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment.
Topics: Animals; Benzamides; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dasatinib; Flow Cytometry; Glycosylation; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Intracellular Space; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Fusion Proteins; Reproducibility of Results; Signal Transduction; Thiazoles | 2009 |
Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Calcium Signaling; Cell Line, Tumor; Cell Separation; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Lymphoma, Large B-Cell, Diffuse; Microscopy, Fluorescence; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases; Thiazoles; Tissue Array Analysis | 2010 |
Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.
Topics: Algorithms; Benzamides; Cell Cycle; Cell Line; Cluster Analysis; Computational Biology; Dasatinib; Diphenylamine; Dose-Response Relationship, Drug; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2009 |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Republic of Korea; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2009 |
Radiosensitization effect of STI-571 on pancreatic cancer cells in vitro.
Topics: Analysis of Variance; Apoptosis; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Formazans; Genes, ras; Humans; Imatinib Mesylate; Mutation; Pancreatic Neoplasms; Phospholipase C gamma; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, Platelet-Derived Growth Factor beta; Tetrazolium Salts; Thiazoles; Time Factors | 2009 |
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2009 |
Lasker Awards and papal portraiture: turning fields upside down.
Topics: Awards and Prizes; Benzamides; Cellular Reprogramming; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orientation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reoperation; Retrospective Studies; Risk; Thiazoles; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Topics: Adult; Benzamides; Cohort Studies; Cytogenetic Analysis; Dasatinib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
Topics: Antineoplastic Agents; Benzamides; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Models, Chemical; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Tetrazolium Salts; Thiazoles | 2009 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2010 |
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Middle Aged; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; Transplantation, Autologous | 2010 |
Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Topics: Anthracyclines; Benzamides; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Imatinib Mesylate; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Small Cell Lung Carcinoma; Tetrazolium Salts; Thiazoles | 2010 |
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System; Child; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemic Infiltration; Mutation; Neoplasm Proteins; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Secondary Prevention; Thiazoles; Transplantation Conditioning | 2009 |
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
Topics: Adenine; Animals; Benzamides; Binding Sites; Cell Line; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzene Derivatives; Cells, Cultured; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Mice; Mutation; Phosphorylation; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Tyrosine | 2010 |
Treatment of Philadelphia-positive acute lymphocytic leukemia with tyrosine kinase inhibitors: What is the optimal regimen?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2010 |
A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
Topics: Adult; Aged; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Diphtheria Toxin; Drug Synergism; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2010 |
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Topics: Animals; Benzamides; beta Catenin; Cell Hypoxia; Cell Line, Tumor; Dasatinib; Humans; Imatinib Mesylate; Lactoylglutathione Lyase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Heterologous | 2010 |
The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Topics: Aluminum Silicates; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytotoxicity, Immunologic; Dasatinib; Down-Regulation; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Interferon-gamma; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
Lck is a key target of imatinib and dasatinib in T-cell activation.
Topics: Animals; Benzamides; Blotting, Western; Chlorocebus aethiops; COS Cells; Dasatinib; Flow Cytometry; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Immunoprecipitation; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; T-Lymphocytes; Thiazoles | 2010 |
Colony stimulating factor-1 receptor as a target for small molecule inhibitors.
Topics: Benzamides; Binding Sites; Carbazoles; Computer Simulation; Dasatinib; Drug Design; Furans; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Staurosporine; Sunitinib; Thiazoles | 2010 |
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Substance Withdrawal Syndrome; Thiazoles | 2010 |
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Molecular Structure; Mutant Proteins; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; src-Family Kinases; Thiazoles; Threonine | 2010 |
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic | 2010 |
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles | 2010 |
Reversible cardiotoxicity with tyrosine kinase inhibitors.
Topics: Adult; Benzamides; Cardiotoxins; Central Nervous System Neoplasms; Dasatinib; Fatal Outcome; Female; Humans; Imatinib Mesylate; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Ventricular Dysfunction, Left | 2010 |
Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CD8-Positive T-Lymphocytes; Clonal Anergy; Clone Cells; Cytomegalovirus; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Immunologic Surveillance; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Thiazoles; Virus Activation; Young Adult | 2010 |
Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Disease Models, Animal; Drugs, Investigational; ErbB Receptors; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Mixed Connective Tissue Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pulmonary Fibrosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Thiazoles | 2010 |
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Culture Techniques; Dasatinib; Humans; Imatinib Mesylate; K562 Cells; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Topics: Antineoplastic Agents; Benzamides; Chromosome Breakpoints; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cells, Cultured; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Mice; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Xenograft Model Antitumor Assays | 2010 |
Even better kinase inhibitors for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2010 |
Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Biosensing Techniques; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fluorescence; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Calcium; Cell Proliferation; Cyclosporine; Cytokines; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Wnt Proteins | 2010 |
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Antigens, Surface; Benzamides; Blood Cells; Bone Marrow Cells; Cell Count; Cytotoxicity, Immunologic; Dasatinib; Female; Flow Cytometry; Humans; Imatinib Mesylate; Immune System; Immunologic Memory; Immunophenotyping; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult | 2010 |
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger; Thiazoles | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Topics: Adult; Aged; Benzamides; Comparative Genomic Hybridization; Dasatinib; ErbB Receptors; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Male; Middle Aged; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma; Thiazoles; Tunica Intima; Vascular Neoplasms | 2010 |
Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Models, Animal; Down-Regulation; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Integrins; Mice; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Up-Regulation | 2010 |
A magnetic bead-based protein kinase assay with dual detection techniques.
Topics: Antibodies; Benzamides; Dasatinib; Imatinib Mesylate; Immunoassay; Luminescent Measurements; Magnetics; Peptides; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thiazoles | 2011 |
Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Biosensing Techniques; Cells, Cultured; Chlorocebus aethiops; Computer Systems; COS Cells; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorescence Resonance Energy Transfer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines; Thiazoles; Time Factors | 2010 |
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Dasatinib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Salvage Therapy; Survival Rate; Thiazoles; Transcription Factors | 2010 |
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2010 |
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland | 2010 |
Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzamides; Blast Crisis; Clofarabine; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Homologous | 2010 |
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation | 2011 |
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p57; Dasatinib; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Transcription, Genetic | 2011 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Survival Rate; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intention to Treat Analysis; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2010 |
Second-generation BCR-ABL kinase inhibitors in CML.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Remission Induction; Thiazoles | 2010 |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
[Chronic myeloid leukemia and targeted therapies: too many choices?].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2010 |
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Protocols; Benzamides; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Thiazoles; Withholding Treatment | 2011 |
[A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia].
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosomes, Human, Pair 3; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; C-Reactive Protein; Complement System Proteins; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunity, Innate; Immunoglobulins; Immunologic Factors; Interferon-alpha; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles; Treatment Outcome | 2010 |
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-gamma; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Role of Pten in leukemia stem cells.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Thiazoles | 2010 |
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Topics: Benzamides; Child; Dasatinib; Diseases in Twins; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Panniculitis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Skin; Thiazoles | 2011 |
Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Piperazines; Pyrimidines; Safety-Based Drug Withdrawals; Thiazoles | 2011 |
Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and donor lymphocyte infusion.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lymphocyte Transfusion; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2011 |
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles | 2011 |
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Duplication; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cross Reactions; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.
Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thiazoles | 2011 |
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2011 |
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Enzyme Activation; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mice; Models, Biological; Mutant Proteins; Phosphatidylinositol 3-Kinase; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; Thiazoles | 2011 |
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles; Vault Ribonucleoprotein Particles | 2011 |
Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS).
Topics: Benzamides; Chromatography, Liquid; Dasatinib; Gene Expression Profiling; Hep G2 Cells; Humans; Imatinib Mesylate; Liver Neoplasms; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; Staurosporine; Thiazoles | 2011 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Topics: Adaptor Proteins, Signal Transducing; Benzamides; Biomarkers, Tumor; Dasatinib; Dose-Response Relationship, Drug; Enzyme Assays; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Thiazoles | 2010 |
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2012 |
[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib].
Topics: Aged; Benzamides; Chronic Disease; Dasatinib; Drug Monitoring; Drug Tolerance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Thiazoles; Treatment Outcome | 2011 |
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromosomes, Human, Pair 8; Clone Cells; Dasatinib; DNA Mutational Analysis; Genomic Instability; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Philadelphia Chromosome; Piperazines; Preleukemia; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Selection, Genetic; Thiazoles; Trisomy | 2012 |
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.
Topics: Antibodies, Monoclonal; Benzamides; Cells, Cultured; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Thiazoles; Up-Regulation | 2012 |
Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Binding Sites; Blast Crisis; Catalytic Domain; Dasatinib; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2011 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |
[Roles of the 2nd generation TKIs for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2011 |
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
Topics: Antineoplastic Agents; Benzamides; Calibration; Cells, Cultured; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Limit of Detection; Mass Spectrometry; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reference Standards; Reproducibility of Results; Thiazoles | 2012 |
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Topics: Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Thiazoles | 2011 |
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Survival Rate; Thiazoles; Time Factors; United Kingdom | 2011 |
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; International Classification of Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome; Young Adult | 2012 |
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome | 2012 |
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors; Young Adult | 2011 |
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.
Topics: Animals; Benzamides; Cell Communication; Cell Differentiation; Collagen; Culture Media, Conditioned; Dasatinib; Drug Combinations; Endocytosis; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; K562 Cells; Laminin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Nanotubes; Neovascularization, Physiologic; Piperazines; Proteoglycans; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors | 2012 |
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Topics: Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles | 2012 |
Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2011 |
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Topics: Antigens, CD34; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Nucleus; Cells, Cultured; Cyclin D1; Cytokines; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maleimides; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; Thiazoles | 2012 |
Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Topics: Adult; Benzamides; Comorbidity; Dasatinib; Disease Management; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; South Africa; Thiazoles; Treatment Outcome | 2011 |
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Agents; Asia, Southeastern; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Delivery of Health Care; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United Kingdom | 2012 |
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Europe; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Validation Studies as Topic; Young Adult | 2012 |
NICE backs leukaemia drug after manufacturer drops price.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Thiazoles; United Kingdom | 2012 |
Pulmonary arterial hypertension in patients treated by dasatinib.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome | 2012 |
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Female; Fusion Proteins, bcr-abl; Germany; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome; United Kingdom; United States | 2012 |
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Topics: Aniline Compounds; Benzamides; Binding Sites; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isomerism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Recombinant Proteins; Spectrophotometry, Infrared; Static Electricity; Thiazoles; X-Ray Diffraction | 2012 |
CML treatment in Asia-Pacific region.
Topics: Adult; Antineoplastic Agents; Asia; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Role of Src tyrosine kinases in experimental pulmonary hypertension.
Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Proliferation; Cells, Cultured; Chemotaxis; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Hemodynamics; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Imatinib Mesylate; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Time Factors | 2012 |
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
Topics: Benzamides; CD28 Antigens; CD3 Complex; Cyclosporine; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lymphocyte Activation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2012 |
[Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2012 |
Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Lineage; Dasatinib; Disease Models, Animal; Drug Resistance; Drug Resistance, Neoplasm; Erythrocytes; Exons; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Mice; Mutation; Phenotype; Piperazines; Polycythemia; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2012 |
[Treatment with a tyrosine-kinase inhibitor of for c-KIT mutation and AML1-ETO double positive refractory acute myeloid leukemia].
Topics: Adolescent; Benzamides; Core Binding Factor Alpha 2 Subunit; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Mutation; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Thiazoles; Transcription Factors | 2012 |
MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
Topics: Antineoplastic Agents; Benzamides; beta-Globins; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Down-Regulation; Erythroid Cells; Gene Expression; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; S-Phase Kinase-Associated Proteins; Thiazoles | 2013 |
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
Topics: Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Dried Blood Spot Testing; Drug Stability; Humans; Imatinib Mesylate; Linear Models; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2012 |
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; RNA, Small Interfering; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromatography, High Pressure Liquid; Dasatinib; Drug Monitoring; Female; Hematocrit; Humans; Imatinib Mesylate; Linear Models; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Thiazoles | 2013 |
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzylamines; Blotting, Western; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Thiazoles | 2012 |
An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents.
Topics: Benzamides; Cell Line; Dasatinib; Drug Discovery; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Mutation; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles | 2012 |
10 years of progress in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles | 2012 |
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Flow Cytometry; Genome, Human; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Progenitor Cells; Myeloid Progenitor Cells; Neoplasms, Second Primary; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2012 |
Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Dasatinib; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hyperglycemia; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Italy; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
[Treatment for de novo chronic myeloid leukemia in chronic phase].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
[Treatment of imatinib-intolerant or -resistant CML patients].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
CML: the good, the better, and the difficult choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Dasatinib; Depression; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States; Young Adult | 2013 |
Synergistic anticancer activity of Thiazolo[5,4-b]quinoline derivative D3CLP in combination with cisplatin in human cervical cancer cells.
Topics: Aminoquinolines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Fragmentation; Drug Screening Assays, Antitumor; Drug Synergism; Female; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; MCF-7 Cells; Piperazines; Pyrimidines; Tamoxifen; Thiazoles; Uterine Cervical Neoplasms | 2012 |
Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps.
Topics: Alkaline Phosphatase; Animals; Anticestodal Agents; Artemisinins; Artesunate; Benzamides; Epilepsy; Glucose-6-Phosphate Isomerase; Humans; Imatinib Mesylate; Neurocysticercosis; Nitro Compounds; Parasitic Sensitivity Tests; Piperazines; Praziquantel; Protein Kinase Inhibitors; Pyrimidines; Taenia; Thiazoles | 2013 |
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2012 |
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Thiazoles; Treatment Outcome | 2013 |
As leukemia options grow, drugs jockey to be first-line therapies.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles | 2013 |
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.
Topics: Animals; Benzamides; Cluster Analysis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyrimidines; Spectroscopy, Fourier Transform Infrared; Thiazoles; Tumor Cells, Cultured | 2013 |
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2013 |
Chronic myeloid leukemia: advances in diagnosis and management.
Topics: Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2013 |
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Biological Transport; Bone Marrow Cells; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Nuclear Proteins; Osmolar Concentration; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2013 |
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Clone Cells; Dasatinib; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Substitution; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA; Thiazoles | 2013 |
Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2013 |
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Thiazoles; Vimentin | 2013 |
[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
Topics: Benzamides; Dasatinib; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Eruptions; Folliculitis; Hair Follicle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles | 2014 |
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; United Kingdom; Young Adult | 2013 |
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles | 2013 |
Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket.
Topics: Adenosine Triphosphate; Benzamides; Binding Sites; Cell Line; Down-Regulation; Erythroblasts; Humans; Imatinib Mesylate; Ligands; Lysosomes; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein Transport; Protein-Tyrosine Kinases; Proteolysis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Thiazoles | 2013 |
[Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2013 |
Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Long Noncoding; Thiazoles | 2014 |
The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Young Adult | 2014 |
[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Topics: Benzamides; Cell Line; Cell Survival; Chromatography, Affinity; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Leukemia; NF-kappa B; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases; Thiazoles | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Flow Cytometry; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Thiazoles; Vincristine; Young Adult | 2013 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Benzamides; Chlorocebus aethiops; COS Cells; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hydrogen Bonding; Imatinib Mesylate; Indoles; Molecular Docking Simulation; Mutation, Missense; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Thiazoles | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Biomarkers, Pharmacological; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Statistical; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Topics: Benzamides; Dasatinib; Europe; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Satisfaction; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States | 2013 |
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine | 2014 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Heme Oxygenase-1; Humans; Imatinib Mesylate; Indoles; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Dasatinib; Drug Substitution; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
[Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Phenotype; Piperazines; Pyrimidines; Thiazoles | 2013 |
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line; Cell Membrane; Dasatinib; Genetic Variation; Genotype; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nitriles; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Transduction, Genetic | 2014 |
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Development and validation of an indirect pulsed electrochemical detection method for monitoring the inhibition of Abl1 tyrosine kinase.
Topics: Benzamides; Calibration; Chromatography, Liquid; Dasatinib; Electrochemical Techniques; Fusion Proteins, bcr-abl; Gluconates; Imatinib Mesylate; Inhibitory Concentration 50; Limit of Detection; Linear Models; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Topics: Animals; B-Lymphocytes; Benzamides; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Vectors; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Retroviridae; Sorting Nexins; Thiazoles; Transfection | 2014 |
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Aged; Benzamides; Capsule Endoscopy; Dasatinib; Drug Substitution; Endoscopes, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Drug Administration Schedule; Female; Flow Cytometry; Genes, T-Cell Receptor; Humans; Imatinib Mesylate; Induction Chemotherapy; Infant; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2015 |
Pneumatosis intestinalis and imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Child, Preschool; Dasatinib; Daunorubicin; Dexamethasone; Drug Substitution; Female; Humans; Imatinib Mesylate; Parenteral Nutrition, Total; Piperazines; Pneumatosis Cystoides Intestinalis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Vincristine | 2014 |
PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Topics: Animals; Apoptosis; Becaplermin; Benzamides; Cell Adhesion; Cell Proliferation; Cell Survival; Dasatinib; Ephrin-B2; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Imatinib Mesylate; Mice; Paired Box Transcription Factors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor Cross-Talk; Receptor, EphB4; Receptor, Platelet-Derived Growth Factor beta; Rhabdomyosarcoma, Alveolar; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Butadienes; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Humans; Imatinib Mesylate; Indicators and Reagents; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Nitriles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyrimidines; Real-Time Polymerase Chain Reaction; src-Family Kinases; STAT5 Transcription Factor; Tetrazolium Salts; Thiazoles; TOR Serine-Threonine Kinases | 2014 |
The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.
Topics: Becaplermin; Benzamides; Cell Proliferation; Cells, Cultured; Chemokine CCL2; Dasatinib; Dose-Response Relationship, Drug; Fibroblasts; Gene Expression Regulation; Glucuronosyltransferase; Graves Ophthalmopathy; Humans; Hyaluronan Synthases; Imatinib Mesylate; Interleukin-6; Interleukin-8; Orbit; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-sis; Pyrimidines; RNA, Messenger; Thiazoles | 2014 |
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Topics: ADP-ribosyl Cyclase 1; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Dasatinib; DNA Damage; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Sirtuin 1; Thiazoles; Tretinoin | 2014 |
PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Synergism; Enzyme Activation; Flow Cytometry; Humans; Imatinib Mesylate; Mastocytosis; Piperazines; Protein Kinase C; Protein Kinase C-delta; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Transfection | 2014 |
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Topics: Aminosalicylic Acids; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Luciferases; Molecular Docking Simulation; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Sulfonamides; Thiazoles | 2015 |
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult | 2014 |
Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia.
Topics: Base Sequence; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles; Translocation, Genetic | 2014 |
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Topics: Aged, 80 and over; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Fatal Outcome; Female; Fibroblasts; Humans; Imatinib Mesylate; Lung Neoplasms; Melanoma; Mutation, Missense; Phosphorylation; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Skin Neoplasms; Spinal Neoplasms; Thiazoles | 2014 |
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Topics: Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Dasatinib; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Patient Care; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; United States | 2015 |
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Topics: Adult; Antineoplastic Agents; Australia; Benzamides; Canada; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Therapy Management; Middle Aged; Piperazines; Practice Patterns, Physicians'; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome | 2015 |
Apparent circular dichroism signature of stirring-oriented DNA and drug-DNA complexes.
Topics: Animals; Benzamides; Benzothiazoles; Binding Sites; Cattle; Circular Dichroism; DNA; Humans; Imatinib Mesylate; Nucleic Acid Conformation; Piperazines; Protein Structure, Tertiary; Pyrimidines; Spectrophotometry, Ultraviolet; Thiazoles; Water | 2015 |
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Cardiovascular Diseases; Dasatinib; Databases, Factual; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Lung Diseases; Middle Aged; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration; Young Adult | 2015 |
Targeting Filarial Abl-like Kinases: Orally Available, Food and Drug Administration-Approved Tyrosine Kinase Inhibitors Are Microfilaricidal and Macrofilaricidal.
Topics: Animals; Benzamides; Brugia malayi; Dasatinib; Female; Filaricides; Imatinib Mesylate; Inhibitory Concentration 50; Larva; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2015 |
Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Substitution; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Thiazoles | 2015 |
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
Topics: Adult; Aged; Aniline Compounds; Antineoplastic Agents; Benzamides; Compassionate Use Trials; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Retrospective Studies; Spain; Survival Analysis; Thiazoles | 2015 |
Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Transcriptome | 2015 |
Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.
Topics: Benzamides; Binding Sites; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; src Homology Domains; Substrate Specificity; Thiazoles | 2015 |
[Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Topics: Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Thiazoles | 2015 |
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Exons; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Insertional; Nucleotides; Piperazines; Pyrimidines; RNA, Messenger; Sequence Analysis, DNA; Thiazoles | 2015 |
Treatment-free remission after stopping second-line dasatinib.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2015 |
Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Colitis; Dasatinib; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Thiazoles | 2018 |
Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Doxorubicin; Fibrosarcoma; Imatinib Mesylate; Mouth Neoplasms; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Thiazoles; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoenzymes; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Thiazoles; Triazines | 2017 |
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
Topics: A549 Cells; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Crystallography, X-Ray; Deoxycytidine; Deoxycytidine Kinase; Drug Design; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Imatinib Mesylate; Models, Biological; Models, Molecular; Phosphorylation; Piperidines; Polypharmacology; Protein Kinase Inhibitors; Proteomics; Pyridines; Thiazoles | 2017 |
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Thiazoles | 2018 |
Vasculogenic and angiogenic potential of adipose stromal vascular fraction cell populations in vitro.
Topics: Adipose Tissue; Animals; Cell Movement; Cells, Cultured; Collagen; Diamines; Drug Combinations; Endothelial Cells; Extracellular Matrix Proteins; Imatinib Mesylate; Laminin; Lipectomy; Neovascularization, Physiologic; Proteoglycans; Rats, Sprague-Dawley; Stromal Cells; Thiazoles; Time-Lapse Imaging | 2018 |
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2021 |
Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thiazoles; Up-Regulation; Veratrum Alkaloids | 2021 |
Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; HEK293 Cells; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Protein Kinase Inhibitors; Quinolines; Thiazoles; Transfection; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |